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Abstract: Within-host genetic sequencing from samples collected over time provides a 
dynamic view of how viruses evade host immunity.  Immune-driven mutations might stim-
ulate neutralization breadth by selecting antibodies adapted to cycles of immune escape 
that generate within-subject epitope diversity.  Comprehensive identification of immune-
escape mutations is experimentally and computationally challenging.  With current tech-
nology, many more viral sequences can readily be obtained than can be tested for binding 
and neutralization, making down-selection necessary.  Typically, this is done manually, by 
picking variants that represent different time-points and branches on a phylogenetic tree.  
Such strategies are likely to miss many relevant mutations and combinations of mutations, 
and to be redundant for other mutations.  Longitudinal Antigenic Sequences and Sites from 
Intrahost Evolution (LASSIE) uses transmitted-founder loss to identify virus “hot-spots” 
under putative immune selection and chooses sequences that represent recurrent mutations 
in selected sites.  LASSIE favors earliest sequences in which mutations arise.  With well-
characterized longitudinal Env sequences, we confirmed selected sites were concentrated 
in antibody contacts and selected sequences represented diverse antigenic phenotypes.  
Practical applications include rapidly identifying immune targets under selective pressure 
within a subject, selecting minimal sets of reagents for immunological assays that charac-
terize evolving antibody responses, and for immunogens in polyvalent “cocktail” vaccines. 
Keywords: human immunodeficiency virus type 1; vaccine; neutralizing antibodies; im-
munogen design; envelope glycoprotein; coevolution; immune escape; quasispecies; anti-
genic swarm; selection 
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1. Introduction 
It is not yet known how to elicit protective immunity against HIV-1, and neutralizing antibody in-
duction remains a central focus of the HIV vaccine field.  Neutralizing antibodies are immune corre-
lates of protection in all antiviral vaccines licensed to date [1,2].  Administration of neutralizing anti-
bodies can confer protection in SHIV challenge models with rhesus macaques [3,4].  During the natu-
ral course of HIV infection, typically a single transmitted-founder (TF) virus establishes infection 
[5,6].  The virus population grows exponentially, with random mutations that initially accumulate fol-
lowing a Poisson distribution of inter-sequence distances [5,6].  The viral load eventually declines and 
resolves to a quasistationary set-point [7], influenced by both host and viral factors [8].  HIV-1 is 
maintained as a continuously evolving quasispecies population throughout chronic infection [9], with 
diversification driven by adaptive immune responses, including antibody [10-18] and T cell responses 
[19-21].  Mutations that facilitate immune evasion are positively selected and become more frequent, 
while mutations that result in a relative fitness disadvantage do not persist.  Though neutral mutations 
may also drift to higher frequency with rates that depend on the effective population size, positive se-
lection exceeds drift at driving envelope evolution within hosts [22-24]. 
During the chronic phase of infection, fifty percent of chronically HIV-1 infected individuals’ anti-
body responses cross-neutralize 50% of HIV-1 primary isolates and breadth of neutralization responses 
varies uniformly across individuals, from neutralization of only a few heterologous viruses, to sera 
with great breadth and potency [17].  Plasma samples from individuals with the most potent and broad 
antibody neutralization are frequently singled out for detailed study [25-28].  Such studies include in-
vestigations of both viral and B cell lineages to understand the immunological processes that elicit 
effective neutralization responses and to inform strategies for vaccine design [15,16,18,29-31].  In 
general, autologous strain-specific neutralizing antibodies (nAbs) begin to develop within the initial 
months after infection, and rapidly select for viral escape variants [11,14].  High titers of more broadly 
neutralizing antibodies (bnAbs) develop in a subset of cases, but only after years of infection, and 
bnAb development is associated with persistently high levels of viral replication [32,33].  Previous 
longitudinal studies of HIV-1 infected individuals have shown that viral diversification precedes the 
acquisition of breadth, which suggests that antigenic diversity may be necessary for bnAb induction in 
vivo [15,18].  Several antibody lineages can place selective pressure on the same epitope at the same 
time, and escape from one antibody lineage can enhance recognition by another lineage, in a delicate 
evolutionary balance [16]. 
Viruses in individuals with bnAbs characterized to date have escaped from otherwise broadly-
reactive neutralizing antibody responses [34].  Antibodies that recapitulate much of the potency and 
breadth of polyclonal sera have been isolated from subjects with high bnAb titers [35,36].  The devel-
opmental pathway of B cell immunoglobulin genes from the initial triggering of an HIV-1 specific 
clonal lineage through the acquisition of potency and breadth later in infection is an active research 
frontier.  Properties of evolving viral Env proteins that stimulate or facilitate the important transition 
from autologous to heterologous reactivity are only beginning to be understood [15,18].  Understand-
ing the events in natural HIV-1 infection that result in broader humoral responses should ultimately 
enable new vaccine strategies to elicit potent, broadly cross-reactive nAbs.  Thus, a continuing re-
search priority has been to characterize virus coevolution with antibodies in individuals who develop 
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the greatest potency and breadth of neutralization [15,16,18,31,37,38].  Working back from mature 
bnAb clonal lineages, through ancestral intermediates, to the unmutated germline precursor, has begun 
to help define the process of bnAb development [15,18,29,30,35,37-40].  To study antibody/viral co-
evolution, analysis of longitudinally (i.e. serially) sampled sequences, which represent both the anti-
body population as it undergoes affinity maturation and the virus population as it evolves to evade the 
ongoing immune responses, explores mutational patterns that are selected over time [15,18]. 
Here we describe a new computational approach, called LASSIE, a two-step process to conduct 
longitudinal sequence analyses and inform reagent design.  The first part of the LASSIE approach al-
lows one to define and visualize sites that are potentially under positive selective pressure in the viral 
population.  Identifying sites under putative immune selection can immediately help guide inference of 
antibody specificities that are active in the plasma, enable tracking of their appearance through time, 
and identify key mutations to be characterized during experimental follow-up studies.  The second part 
of the approach is an algorithm that objectively down-selects sequences from a much larger sequence 
sample, yielding a subset of viral variants that represent mutations among the selected sites.  We call 
the resulting subset of sequences an “antigenic swarm,” which captures mutations at sites that are un-
der the most potent selective pressure as they first emerge in the evolving HIV-1 quasispecies 
[15,18,31].  The size of the sequence subset involves a trade-off between the experimental cost of in-
cluding more variants and the degree of selection to be represented.  LASSIE involves two parameters 
that can be adjusted to balance these factors, explore the data, and choose the most representative set 
given experimental feasibility and sample-size limitations.  To validate LASSIE, we retrospectively 
analyzed the Env quasispecies complexity in an African HIV-infected individual (CH505), for which 
we already have extensive information regarding antibody interactions and targeted Env epitopes 
[15,16].  This approach allowed us to determine how well the relevant diversity was captured by our 
computational method. 
LASSIE can be used to select Envs (or similarly diversifying variants) for expression and binding 
studies, or to generate pseudoviruses for use in neutralization assays.  In turn, the resulting reagents 
can be used to study relationships between viral phenotype and genotype, and to investigate in detail 
how neutralizing antibody responses develop by affinity maturation.  Moreover, the chosen Envs can 
be used as experimental polyvalent “swarm” HIV vaccine immunogens. 
2. Materials and Methods 
2.1. Overview 
LASSIE analyzes a multiple sequence alignment in two phases.  The first phase identifies protein 
sites most likely to be under positive (diversifying) selection, by considering the extent to which the 
TF amino acid state is “lost,” i.e. replaced by mutations or deletions, at any one time-point during lon-
gitudinal sampling.  This yields a list of sites of interest, from which we tabulate and track amino acid 
mutations that appear over time.  TF loss is a simple and useful strategy to identify candidate sites un-
dergoing positive selection in a scenario such as HIV evolution in vivo [41].  Profound immunological 
pressure can result in a selective sweep, where a mutation in a site is fixed and persists after its initial 
introduction, and such a mutational event may occur only once in a reconstructed phylogenetic history.  
Longitudinal Antigenic Swarm Selection from Intrahost Evolution Hraber et al. 
 
Page 4 of 55 
Such sites may be critically important to the evolving immunological phenotype of the virus, and 
would be good candidates for attention in experimental work.  However, they would be undetected in 
commonly used statistical methods to detect positively selected sites.  This is because the common 
methods require recurrence of mutational patterns in a tree for statistical validation, to identify ratios of 
non-synonymous to synonymous mutation rates significantly greater than one [42-44]. 
In contrast, our goal is to identify inclusively the sites that are candidates for being under positive 
selection pressure, as quantified by the extent of transmitted-founder loss [41].  To motivate use of the 
TF loss criterion, we performed a detailed comparison using both MEME [44] and LASSIE with longi-
tudinal sequences from CH505, described in Results.  LASSIE also provides plotting functions to re-
view variation in selected sites over time.  Comparing the list of selected sites with previously de-
scribed antibody contacts from the growing set of anti-HIV bnAbs can facilitate the search to charac-
terize immune responses that drive sequence diversification in newly obtained samples.  The second 
phase of analysis uses the list of selected sites to choose sequences that represent the natural accrual of 
mutational variants that occur more than once among selected sites.  The two phases of analysis, and 
parameters that influenced the number of sites and sequences thereby obtained, are detailed below. 
An important feature of the single-genome amplification (SGA) sequences analyzed below is that 
they were obtained by limiting-dilution PCR, which provides genetic linkage across all of the env 
gp160, without in vitro recombination artifacts, and limited nucleotide substitution errors in cDNA 
synthesis [45,46].  Unlike Sanger sequencing from bulk PCR or large numbers of fragmentary high-
throughput reads from unlinked templates, SGA sequences can provide high-quality sequence data 
spanning intact genes, ideally suited to understand how viruses adapt to host immune responses over 
time [5,14,21,45-47]. 
2.2. Site Selection 
We analyzed env cDNA amplicon sequences from plasma viral RNA by single-genome amplifica-
tion (SGA), also known as limiting-dilution PCR [45], sampled longitudinally, beginning early (4 
weeks) after infection, with three years of clinical follow-up.  The sequencing effort was intended to 
obtain about 20 sequences (median of 25, range 18-53) from each of 14 samples.  SGA sequencing 
from homogeneous infections commonly yields multiple identical sequences, all of which we kept.  
(Because they produce “rakes” of identical sequences on phylogenetic trees, monotypic sequences con-
tain information about evolution and allele frequencies in the population sampled, but are incompatible 
with methods that require phylogenies with strictly dichotomous branching.  We revisit this issue in 
the Discussion.)  A naming convention for Env sequences was used to ensure consistency and to ena-
ble parsing of sample time-point labels from sequence names.  By default, time-point labels are as-
sumed to be in the first dot-delimited field of each sequence name, though any character could separate 
fields and they need not be in the first position.  To study variant dynamics, we computed the number 
of days elapsed after the earliest sample from sample dates, and added the number of days post-
infection estimated from the earliest sample.  For homogeneous infections sampled before the onset of 
immune selection, such as subject CH505, a simple Poisson model of random sequence evolution pro-
vides the estimate [5,6]. 
Longitudinal Antigenic Swarm Selection from Intrahost Evolution Hraber et al. 
 
Page 5 of 55 
We added the HXB2 reference sequence to standardize site numbering, codon-aligned the sequenc-
es, translated them, and inferred a phylogeny.  Accurate alignment of the hypervariable loops, which 
evolve by insertion and deletion, is difficult for automated algorithms.  Because no algorithm aligns 
the HIV envelope perfectly, particularly when a translation is needed, we manually edited the prelimi-
nary alignment, which was based on an HIV-specific hidden Markov model [48,49], for consistent and 
compact loop regions.  PhyML v3 inferred maximum-likelihood trees from translated amino-acid se-
quences with the HIVw (HIV-specific, within-host) substitution model [50-52].  The phylogeny was 
used to order sequences for visualization and provides an organizing principle for sequence evolution 
from the ancestral TF virus.  Reordering the alignment to follow the phylogeny was used to review 
alignment accuracy and consistency among closely related sequences.  To identify potential N-linked 
glycosylation (PNG) sites readily, we annotated PNG sites, replacing asparagine sites that match the 
Nx[ST] motif to become Ox[ST].  In the PNG motif, x indicates any amino acid except proline, and 
the third position is either serine or threonine.  To identify selected sites, the gaps inserted to maintain 
an alignment are considered a character state, because HIV frequently evolves by insertion and dele-
tion, in addition to point mutations.  For each aligned site, we computed TF loss per time-point se-
quenced, identified the maximum, and compared this peak TF loss with a threshold.  We adjusted the 
threshold and considered the resulting number of sites.  This produced a list of sites, which we consid-
ered as interesting evolutionary “hot spots”, to be represented by a swarm of Envs for experimental 
design. 
We identify selected sites by transmitted-founder (TF) loss, defined as the proportion of sequences 
sampled per time-point that mutated away from the ancestral TF state.  This is an efficient and inclu-
sive way to identify rapidly evolving sites [41].  Because immune pressures can be transient, a variant 
may be relevant in only a particular phase of antibody lineage development.  Thus, by considering TF 
loss per time-point, we seek to identify mutations that may be transiently important for resistance pro-
files of developing B-cell lineages.  Here we considered no other information than TF loss per time-
point, though other information could be used, so an option to specify additional sites for inclusion 
with the automatically selected sites is available.  For example, signature sites associated with neutrali-
zation assay outcomes, antibody contact residues from structural data, key glycosylation sites associat-
ed with common bnAb epitopes, and additional sites identified using other methods (e.g. [42-44]) can 
be included by listing them for subsequent evaluation, even when these sites do not meet the minimum 
TF loss criterion.  Similarly, if excessive diversity in hypervariable loops needlessly increases the 
number of sequences selected, such sites can be excluded simply by listing them. 
Calculations of cumulative TF loss weighed the TF loss for two consecutive samples by the amount 
of time elapsed between when the two samples were drawn.  Use of cumulative TF loss distinguished 
between sites that reverted to the TF form and sites that quickly mutated away from the TF and never 
reverted, and between sites that changed at different rates.  For an informative representation of the 
accumulation of mutations among selected sites during site selection, we sorted sites by two criteria: 
time to initial TF loss and cumulative TF loss.  The ordered list of selected sites identified automatical-
ly by LASSIE, or added specifically by choice, forms a “concatamer” by stringing together the listed 
sites extracted from a full-length sequence. 
2.3. Sequence Selection 
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After having used the TF-loss criterion to select sites from the alignment, we identified a set of 
Envs to represent the mutations that occur at these sites.  By simple combinatorics, there are at least 
10100 distinct ways to choose k representatives from n individuals for n above 427 and k over 100.  On 
the scale of the current example, choosing 50 representatives from 385 candidates gives over 1063 dis-
tinct alternatives.  To search such a vast space of possible solutions is intractable for even the fastest 
computers.  Worse, in the regime of interest, the number of alternative solutions grows exponentially 
with k, where k << n/2.  To our knowledge, there is no established optimality criterion for choosing 
representative variants from a larger set of aligned sequences.  The second phase of analysis provides a 
practical solution to the problem, which we consider as a working proxy for an optimal solution [53]. 
As outlined in Figure 1, the swarm selection algorithm identifies sets of sequences that recapitulate 
viral evolution in key residues from a table of the amino acid mutations that occur in each site selected 
in the first analysis phase.  Mutations that only ever appear once, or less than some other minimum 
number of times if specified, are disregarded.  This parameter, the minimum variant count, is set to two 
by default.  The resulting table lists all mutations to be included in the swarm set of Envs.  Candidates 
for Env selection must be functionally viable, by lacking long deletions (as specified by the operator of 
the algorithm) and premature stop codons or incomplete codons, which typically result from frame-
shift mutations. 
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Figure 1. Swarm selection algorithm.  From a sequence alignment and list of selected 
sites, this approach identifies viable Envs and tabulates mutations in selected sites.  The ta-
ble is used initially to define which mutations will be represented by the swarm, and is used 
subsequently to keep track of which mutations remain to be included.  Rare mutations, i.e. 
mutations detected fewer times than the minimum variant count over the entire sampling 
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period, are disregarded.  Selection among multiple sequences that carry a mutation is re-
solved by minimizing a series of distance criteria, first to minimize Hamming distance 
(number of mutations, gaps included) to the TF form among selected sites, then distance to 
the full-length TF sequence, and finally to minimize average distance to sequences in the 
current swarm set.  The selected Env is included in the swarm set, counts in the table of 
needed mutations are set to zero, to indicate the particular mutation is now covered in the 
swarm, and iteration continues.  This produces a “swarm” of Envs, which represents diver-
sity in selected sites as it first developed within the subject, given sampling constraints.  
Stacked boxes signify iteration.  Unresolved ties are reported, though we have not yet en-
countered them in several large experimental sequence sets we have tested; such an out-
come would signal the need for an alternative distance metric or more selection criteria. 
Building a swarm set starts with the TF sequence.  If working with sequences that were first sam-
pled during chronic infection, the natural sequence most similar to the consensus from the first availa-
ble time-point is a good alternative.  Sequences from the earliest time-point sampled are then consid-
ered, and scanned for the presence of sites with amino acids represented in the table of mutations.  If a 
particular mutation of interest is present in one or more sequences from the first time-point, the choice 
among multiple Envs that carry a needed mutation is resolved by a series of criteria.  The algorithm 
first tries to identify the sequence that uniquely minimizes the distance (number of mutations, includ-
ing gaps) to the TF among selected sites.  Then, in case of ties, a sequence is chosen that minimizes 
distance to the full-length TF.  Finally, if ties remain, the sequence chosen minimizes the average dis-
tance to the current working set of sequences (Figure 1).  An option exists to require that specific se-
quences be included, if desired.  Such a sequence is added during iteration, when the time-point from 
which the sequence was sampled is being evaluated, rather than beforehand, to ensure inclusion of 
earlier (less divergent) sequences that carry mutations found on the specified sequence.  After iterating 
over sample time-points, needed mutations, and selected sites, swarm selection is complete.  Unre-
solved ties may exist among alternative sequences for some data.  Such remaining ties would indicate a 
need for an alternative distance metric or additional selection criteria, though we have not yet encoun-
tered this outcome using Hamming distances from matching amino acid sequences and the three selec-
tion criteria described. 
The algorithm is deterministic, which means it will always produce the same set of sequences from 
a given alignment, because it does not make random choices, and does not depend on the order in 
which sequences are provided in the input alignment.  Overall, an advantage of this approach is that it 
selects no more sequences than are necessary to represent the mutational variants in selected sites, ra-
ther than some arbitrary number.  By design, this greedy approach favors inclusion of early point mu-
tations.  This strategy produces larger sets of sequences than would result from favoring later, more 
divergent Envs that carry a greater number of needed mutations, but it better recapitulates the gradual 
increase of diversity in the evolving virus population.  Among selected sites, each mutation observed 
more than once will ultimately be included in the antigenic swarm, generally multiple times if it re-
mains common in subsequent time-points.  The algorithm identifies the first appearance of mutations 
of interest in the least divergent sequence background possible, among available sequences sampled.  
It does this by progressively covering mutations that occurred in selected sites in the first time-point 
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they appeared, and by representing them with the sequence most similar to the TF or, to resolve ties, 
the sequence most similar to those under consideration (lower-right quadrant in Figure 1). 
The algorithm was made efficient through use of vector operations, and computes distance matrices 
only when they are needed to choose between otherwise ambiguous alternatives.  Its duration of execu-
tion is expected to require no worse than a linear increase with the number of sequences and sample 
time-points in the input alignment.  That is, doubling the number of input sequences or sample time-
points should no more than double the run time.  This was consistent with our experiences applying 
LASSIE to other large longitudinal data sets. 
The methods to select sequences and sites and to plot the results graphically were written as an 
open-source (GPL v2) R package called lassie (github.com/phraber/lassie).  Develop-
ment activities are underway to provide lassie as a web-enabled service via the LANL HIV database.  
The package includes aligned sequences from CH505 and a tutorial vignette.  The methods used in this 
paper to plot variant frequencies are included with the lassie package.  We have included the Gen-
Bank accession numbers (KC247375-KC247667 and KM284696-KM284799) with those data.  The 
env sequences from chronic infection in CH0457 are also in GenBank (KT220796-KT221004). 
To visualize variation among descendants sampled serially from within a host, we have paired phy-
logenetic trees (rooted on the TF virus, ladderized, then rendered as phylograms) together with pixel 
plots [54,55], which illustrate polymorphisms as either mutations or indels relative to the TF sequence.  
We find these to be informative representations for understanding evolution of the virus population in 
an acutely infected host, given the limited genetic diversity that occurs in early infections [15,56].  
Renderings such as given below emphasize sites with evolutionary changes that produce the branching 
patterns in the tree, and enable detection of recombinant clades or evolutionary associations with phe-
notypic assays.  The code we use to make such renderings was written as an open-source R package 
called pixgramr (github.com/phraber/pixgram), and uses ape to draw trees [57]. 
2.4. Positively Selected Sites by MEME and FEL Analyses 
We analyzed the CH505 env codon alignment using the DataMonkey server (datamonkey.org) [58].  
Because the alignment was too large for GARD recombination analysis and used directly for MEME 
and FEL analyses [44,59], these results are limited by to caveat that recombination was not excluded.  
We used the GTR/REV model of base substitution [60,61], and all sites with p-values below 0.1 were 
considered.  Nine sequences with premature stop codons were excluded.  After removing these and the 
duplicated sequences, 333 sequences remained. 
2.5. Clinical Sample Assays 
Procedures for binding and neutralization assays have been described elsewhere [15,16,56].  Clini-
cal materials were obtained as a part of the CHAVI 001 observational study.  All participants in that 
study gave their informed consent before they participated in the study, which was conducted in ac-
cordance with the Declaration of Helsinki.  The Kilimanjaro Christian Medical Centre Research Ethics 
Committee, the Tanzania National Institute for Medical Research Ethics Coordinating Committee, and 
the Duke University Institutional Review Board approved studies involving human subjects from 
whom we obtained materials with results described herein. 
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3. Results 
Building upon recent insights into antibody/Env coevolution in individual CH505 [15,16,56], we 
first applied LASSIE to this subject as a test case, to determine how well the method performed in a 
situation where key epitopes had already been defined and characterized.  We aligned 385 sequences 
from 14 time-points sampled over three years across 953 Env sites and computed TF loss (Figure 2). 
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Figure 2. Loss of ancestral transmitted-founder (TF) amino acids in Envs from 
CH505.  For 953 aligned Env sites spanning the full-length protein, TF loss is proportion 
of non-TF mutations per time-point sampled from the study participant CH505.  TF loss is 
computed for each of 14 time-points sampled longitudinally, weeks 4 through 160, with the 
number of Envs sequenced (n) per time-point as shown.  Bar colors vary over time to indi-
cate 35 sites with at least 80% TF loss in any time-point, whether at peak TF loss (pink), 
below peak but above the 80% cutoff (brown), or below 80% (blue).  Variable sites that 
were not selected for further consideration, because they never exceeded 80% TF loss in 
ant time-point during the study period, are also depicted (black bars).  Grey boxes identify 
variable loops, which contain hypervariable regions that evolve by insertion and deletion 
and other gp120 landmarks.  A thin grey line marks the boundary between gp120 and gp41.  
The time (t) of the sample is shown as days post infection (dpi), and the number of se-
quences (n) available from each time-point is shown.  The gp160 site numbers indicate 
HXB2 positions in the CH505 protein alignment. 
3.1. Site Selection 
Figure 2 shows TF loss per site for each time-point sampled, from week 4 through week 160 post-
infection.  Clearly, most sites show little or no TF loss.  Sites with high levels of TF loss are putative 
escape mutants due to immune selection.  Because we counted an insertion or deletion relative to the 
TF virus as a change, the hypervariable V1, V2, V4, and V5 regions also showed TF loss, largely due 
to length variation.  We used TF loss to list sites where frequency of the TF form fell below a fixed 
cutoff percentage.  The cutoff is a parameter that can be adjusted as needed; here we used the value of 
80% TF loss in samples from at least one time-point.   
3.1.1. TF Loss Varied across Sites 
Initially dominated by the TF form, the quasispecies acquired mutational variants over time, dis-
playing different dynamics among sites with high TF loss.  Figure 3 depicts variant frequencies in 
subject CH505 over time in the 35 sites shown, which had over 80% TF loss in at least one time-point.  
The rate of TF loss was slower in some sites than in others.  Such slow transitions could reflect the 
evolving immune response and newly arising selective pressure.  In qualitative terms, we saw four 
dynamic categories, designated i-iv.  First (i), some sites showed complete replacement of the TF form 
with another single variant, whether fast or slow, e.g. the shift of a glycosylation site from position 334 
to 332 (top-right panel “N332” in Figure 3, N → O, and O334 in the next row, from O → S, where 
“O” is an asparagine embedded in a glycosylation motif, as described in Section 2.2).  Next (ii), in 
some sites, the initial TF replacement was followed by one or more additional mutations arising se-
quentially.  For example, site 279, located in Loop D, was initially an asparagine, but a transient lysine 
mutation yielded to an aspartic acid after transient reversion to the TF asparagine (Figure 3, top-left, N 
→ K → N → D).  Third (iii), some sites reverted to the TF form after high TF loss.  For example, site 
417, initially histidine, was predominantly an arginine from about six months to nearly two years after 
infection, but then reverts to the ancestral histidine  (Figure 3, top row, second panel, H → R → H). 
Finally (iv), some sites exhibited sustained polymorphisms.  These were particularly common in hy-
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pervariable loops, in which insertions and deletions are the predominant evolutionary processes.  In 
such cases, distinct subpopulations may carry forward divergent forms.  For example, several distinct 
insertions arise in the V1 loop, which follow HXB2 position 144, and some of these forms are main-
tained at different frequencies (Figure 3, middle of the second row, 144g, 144h, and 144i).  When such 
patterns are located in hypervariable regions, they may be alignment dependent, and should be re-
viewed in the context of the full alignment to ensure that they represent distinct and common forms of 
the hypervariable loops of the viral quasispecies, and not simply alignment artifacts. 
 
Figure 3. Variant frequency dynamics within sites.  The single TF virus amino acid 
(dashed lines) yields to putative escape mutations over the sampling period.  Letters below 
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each plot list mutations in order of appearance, and panels are ordered according to the tim-
ing of TF loss.  Numbers above each plot denote TF form, HXB2 position, and alignment 
column, e.g. “N279 [357]” indicates HXB2 position 279 (alignment column 357) and de-
picts loss of the transmitted asparagine.  Lower-case letters denote insertions at the C-
terminal end of the HXB2 site given.  Colors indicate positive (blue) and negative (red) 
charges and an “O” is used instead of “N” to indicate a potentially gylcosylated asparagine 
(cyan), i.e. an N that is embedded in a glycosylation motif of Nx[ST], where x can be any 
amino acid except Pro, followed by either Ser or Thr.  The vertical bars indicate the sam-
pling year, abbreviated in the upper left panel as Y0, Y1 and Y2, with a single TF virus 
starting at Y0, then followed by the first time-point sampled, estimated to be 28 days post 
infection for CH505 [15].  Shaded regions show 95% confidence intervals for variant fre-
quencies, computed from the binomial probability distribution, given the number of se-
quences sampled per time-point.  Several distinct insertions arise after HXB2 position 144 
in the V1 loop, shown in panels in the middle of the second row as 144f, 144g, and 144h.  
Lower-case letters (f through h) specify the relative positions of the inserted region in the 
alignment [62].  The TF lacks an amino acid in this position, which is characterized as a 
gapped state and represented by a dash (–) to maintain the alignment.  Over time, new and 
distinct insertions arise that span this position, with major and minor variants carried along 
with distinctive insertions occurring at positions 144f, 144g, and 144h (e.g. in 144g, three 
different insertions are maintained, which include A, I and T). 
We sampled a median of 25 (range 18-53) sequences across 14 time-points, and sampling 18 se-
quences, our minimum, has 85% probability to detect variants with prevalence 10% or more.  In Fig-
ure 3 we show the dynamics with 95% confidence intervals estimated for the frequencies.  For clarity, 
the mutations that never attain 15% frequency in any sample are not shown.  Given our sampling con-
straints, we could estimate relative frequencies of the different mutational classifications described in 
the paragraph above.  Simple shifts, like (i), were the most common form of TF loss, evident in 16 of 
the 35 selected sites (46%).  Serial mutations, like (ii), were also common and could be the direct result 
of serial escape, due to new pressures imposed by adaptation of the evolving antibody response to an 
initial escape mutation, driving continued selection.  Alternatively, serial replacements could result 
from complex interactions with multiple antibodies in a polyclonal response [16], or pressures result-
ing from balancing fitness costs and/or compensatory mutations in a changing evolutionary milieu.  
Transient losses (iii) reverting to the TF form were rare, and clear restoration of the TF as the dominant 
form after a loss of at least 80% occurred in only 2 of 35 positions (6%), positions 417 and 462 (Fig-
ure 3).  Position 279 had a transient reversion to the TF form, and position 145 may have been revert-
ing at the last time-point sampled.  Different underlying reasons for this pattern could be at play, such 
as a fitness cost for a mutation that was carried along with a neighboring mutation, or a changing im-
munological environment in the host, which could transiently favor a mutation with a modest fitness 
cost [14,63-65]. 
3.1.2. Peak TF Loss Identified Selected Sites 
Longitudinal Antigenic Swarm Selection from Intrahost Evolution Hraber et al. 
 
Page 14 of 55 
We defined “peak” TF loss per site as the highest TF loss in that site over all time-points sampled (of-
ten the “peak” was maintained over many samples), and used it to select candidates for sites under 
immune selection.  Together, 15 sites completely lost the TF form during the three-year sampling peri-
od, while the other 938 aligned sites never reached 100% TF loss.  The cumulative distribution of peak 
TF loss per site (Figure 4) indicated that 588 of 953 sites (62%) were strictly invariant, and 64 (6.7%) 
lost over 50% TF.  We selected the 35 sites with at least 80% peak TF loss for further study and Env 
selection.  The 80% cutoff is the threshold we chose to use for this presentation of these data.  Increas-
ing the TF loss cutoff decreases the number of sites selected, and working with other cutoff values can 
adjust the number of selected sites for subsequent investigation.  This value can be chosen in light of 
available resources. 
 
Figure 4. Cumulative distribution of peak TF loss over 953 aligned Env sites.  Peak TF 
loss is the greatest proportion of non-TF variants in any time-point sampled, which corre-
sponds to the minimum for each dashed line in Figure 3.  Of 953 aligned sites, 365 
(38.3%) varied and the others did not vary among sequences sampled throughout the peri-
od studied.  We selected 35 sites with at least 80% peak TF loss for further study.  Other 
cutoff values would yield more (e.g. 48 at 60% TF loss) or fewer sites (e.g. 15 at 100% 
loss) for consideration. 
3.1.3. Selected Sites were Consistent with Antibody-Driven Selection 
The time at which TF loss started to emerge at each selected site in the sampled virus population 
naturally varied from one site to another (Figures 2 and 3).  The cumulative amount of TF loss also 
varied.  Cumulative TF loss over time had a simple geometric interpretation as the area above the 
dashed TF line in the plots of frequency over time that appeared in Figure 3. 
Table 1 lists the 35 selected sites with at least 80% peak TF loss, ranked by the earliest time at 
which any non-TF variant exceeded 10%, with ties resolved by cumulative TF loss sorted in descend-
ing order.  Most (91%) of the selected sites occurred in gp120. 
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Table 1. Selected sites.  Summary of the extent of TF loss and timing of the mutation in the subject.  
These CH505 Env sites showed at least 80% TF loss in at least one time-point.  Symbol color in left 
column indicates known immune pressures in CH505 that likely drove selection (Figures 5c and 5f). 
 
HXB2 
Site 
Peak 
loss 
When 
up Rank 
MEME 
p-value1 
Immune 
pressure Notes 
 4 87.5 d701 33 NA NA Signal peptide 
•  130 87.5 d547 28 0.086 CD4bs PNG site at base of V1, near VRC01 contact [66] 
•  132 83.3 d547 31 * CD4bs V1 indels cause CH103 resistance [16] 
•  144f 100 d141 9 * CD4bs V1 indels cause CH103 resistance [16] 
•  144g 100 d141 7 * CD4bs V1 indels cause CH103 resistance [16] 
•  144h 100 d141 8 * CD4bs V1 indels cause CH103 resistance [16] 
•  145 96.8 d141 11 * CD4bs V1 indels cause CH103 resistance [16] 
•  147 91.7 d547 29 * CD4bs V1 indels cause CH103 resistance [16] 
•  151 83.3 d371 24 * CD4bs V1 indels cause CH103 resistance [16] 
•  185 83.3 d547 32 0.013 CD4bs Signature site for CD4bs bnAb b12 [67] 
•  234 100 d211 15 NA CD4bs Signature site for CD4bs VRC01 & NIH45-56 [67] 
•  275 91.7 d547 26 0.044 CD4bs Loop D, CH103 contact, CH235 resistant [15,16] 
•  279 95.8 d28 1 0.090 CD4bs Loop D, CH235 resistant, CH103 sensitive [15,16] 
•  281 100 d64 3 0.00007 CD4bs Loop D, CH235 resistant, CH103 sensitive [15,16] 
•  300 100 d211 14 NA V3 loop V3 autologous nAb in CH505 [56]   
•  302 100 d211 16 NA V3 loop V3 autologous nAb in CH505 [56]  
•  325 83.3 d141 12 NA V3 loop V3 autologous nAb in CH505 [56] 
•  330 100 d157 13 NA V3 loop V3 autologous nAb in CH505 [56] 
•  332 100 d141 5  V3 loop V3 autologous nAb in CH505 [56] 
•  334 100 d141 6 0.029 V3 loop V3 autologous nAb in CH505 [56]  
•  347 83.3 d371 23 0.0074 CD4bs 15-17 Angstroms from CH103 contacts 
•  356 100 d547 25 0.018 CD4bs Adjacent to CD4bs bnAb 12A12 signature [67] 
•  398 91.3 d371 22 0.0088 CD4bs 15-17 Angstroms from CH103 contacts 
•  412 83.3 d1121 35 NA CTL CTL epitope V4 loop [16] 
•  413 88.2 d64 4 0.00004 CTL CTL epitope V4 loop [16] 
•  417 91.2 d51 2 0.00073 CTL/CD4bs CTL epitope V4 loop; CD4bs b12 contact [16] 
•  460 100 d371 21 * CD4bs V5, CH103 contact region, resistance [15,16] 
•  462 89.3 d211 19 * CD4bs V5, CH103 contact region, resistance [15,16] 
•  463e 100 d371 20 * CD4bs V5, CH103 contact region, resistance [15,16] 
•  464 100 d211 18 * CD4bs V5, CH103 contact region, resistance [15,16] 
•  465 100 d211 17 * CD4bs V5, CH103 contact region, resistance [15,16] 
•  471 87.5 d547 27 0.0057 CD4bs CH103 contact [16] 
•  620 91.7 d953 34 0.0026 NA gp41 
•  640 83.9 d547 30 0.0054 NA gp41 
•  756 92.9 d141 10 0.0035 NA gp41 cytoplasmic tail 
                                                
1 In the MEME p-value column, an asterisk (*) indicates a site in hypervariable regions of V1 or V5, 
where evolution is enhanced by insertions and deletions.  Because this mode of evolution fails to satis-
fy assumptions of the statistical model, the p-values (false-positive rates) are not readily interpreted.  
Regardless, MEME found support for positive selection in these regions.  “NA” indicates no associa-
tion with positive selection was found with p below 0.1.  Bold text indicates MEME q-values (false 
discovery rates) below 0.2. 
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In the context of the Env trimer structure, the selected sites formed three localized clusters on the 
outer domain of gp120 (Figure 5).  The clustered patches of selected sites on gp120 corresponded to 
the three known regions of immunological pressure in individual CH505.  The first cluster of three 
selected mutations (HXB2 positions 412, 413, 417) was in a CTL epitope, which was targeted early in 
infection in CH505 and conferred early CTL escape [16].  The second cluster of six selected sites (300, 
302, 325, 330, 332, 334) was located within the V3 loop, or in the glycosylation site at its base.  Two 
autologous neutralizing anti-V3 antibodies, DH151 and DH228, were isolated from CH505.  These 
antibodies could only neutralize heterologous Tier 1 viruses at the heterologous population level, but 
potently neutralized a subset of autologous CH505 Tier 2 viruses, shown by linear peptide array bind-
ing to target a linear epitope in the V3 loop, which encompass the V3 loop sites in this second cluster 
[56].  Thus, this second cluster of V3 sites may be relevant to escape from members of this nAb line-
age. 
 
Figure 5. Selected sites are localized to the known immunogenic regions in CH505, as 
visualized by mapping on the BG505 SOSIP trimer structure (PDB ID 4TVP [68]).  Se-
lected sites are depicted as spheres, colored to indicate the timing of their emergence.  (a) 
Side view, oriented with viral membrane towards bottom.  (b) Additional colored high-
lights indicate known immunogenic regions.  (c) Selected sites are colored to show which 
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immune pressures are known to have induced TF loss.  (d-f) The corresponding details 
from top view, as seen from host cell membrane.  Table 1 lists symbol colors for each se-
lected site. 
The third cluster, in the CD4 binding site (CD4bs), is the most complex.  The CD4bs is the target of 
both the CH103 bnAb lineage [15] and the CH235 nAb cooperative lineage [16] in subject CH505.  
Many of the 32 selected gp120 sites included structurally defined contacts for CD4 [66,69], and sever-
al previously studied CD4bs bnAbs, including VRC01 [66,69], NIH45-46 [70], and b12 [71] (Table 
1).  Although the current study is retrospective, this pattern of mutations indicates the presence of 
CD4bs antibodies in the subject, even prior to isolation of CH235 and related nAbs at week 41 [16], as 
this region was apparently under selective pressure very early, particularly in the loop D region [72].  
As expected, CH103 contacts and previously characterized resistance mutations were well represented 
among the selected sites [16].  Three selected sites (279, 281, 275) were localized to CH103 light-
chain contacts near loop D (Figure 5), a region that rapidly accumulated mutations as a result of es-
cape from the autologous CD4bs neutralizing antibody CH235; these mutations rendered the virus 
more susceptible to the CH103 early lineage members.  Six CH103 heavy-chain contacts in and near 
V5 (460, 462-465, 471) were also among the selected sites, and mutations in this region conferred 
CH103 resistance [73].  V1 loop mutations also conferred CH103 resistance, and seven sites in V1 
were among the 35 selected sites (132, 144f, 144g, 144h, 145, 147, and 151).  Three of these were in-
serted together in V1 after position 144.  Finally, 5 additional selected sites are known to be important 
for other CD4bs bnAb interactions, providing indirect evidence that they may be important for either 
CH103 or CH235, or both.  These are: 417, a contact for the CD4bs bnAb b12 [71], and 185, a V2 
region signature site for b12 [67]; 234, a signature site for CD4bs bnAbs VRC01 and NIH45-46 that is 
near Loop D [67]; the glycosylation site N130, adjacent to a VRC01 contact [66]; and position 356, 
adjacent to a 12A12 signature [67].  We identified selected sites that were relevant to the other anti-
bodies noted in this section using the Los Alamos HIV-database genome browser and CATNAP tool 
(hiv.lanl.gov). 
Together, 29 of the 35 selected sites (83%) are related to the three epitopes that were functionally 
defined in this subject during the time period under study, despite these sites being simply and objec-
tively identified based solely on the TF loss criterion (Table 1).  Of the six sites that were not directly 
related, three were gp41 sites (620, 640, 756) and one was in the signal peptide (position 4).  The other 
two (398 and 347) were clustered near position 356 in gp120, and both were near but not in the CH103 
contact region (indicated in Figure 5c as 15-17 Angstroms away from CH103 contacts).  These six 
mutations in sites selected by TF loss are indirectly implicated as having biological or immunological 
significance, and may suggest strong leads for follow-up experimental investigation. 
3.1.4. Comparison of Selected Sites Identified by LASSIE and Phylogenetic Methods 
MEME is an analysis method that identifies sites under episodic diversifying selection within a phy-
logenetic reconstruction [44], and represents a class of tools that identifies positive selection by com-
paring relative levels of synonymous and non-synonymous mutations in the dataset.  While such tools 
are very useful, their application comes with several caveats.  Here we compare the sites identified by 
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the two methods, MEME and LASSIE, which correspond to several dynamic categories.  Using LAS-
SIE, we identified 35 sites with the TF loss criterion, while MEME identified 14 sites of highest inter-
est, with a q-value (false-discovery rate) below 0.2. 
Both methods identified multiple sites in the V1 and V5 hypervariable regions, 8 sites with LASSIE 
and 9 sites with MEME.  Identifying these regions as foci of positive selection is appropriate, because 
changes in both V1 and V5 have been shown to confer distinct immunological phenotypes with respect 
to the evolving nAb lineages in subject CH505 [15,16,73].  However, a concern for interpreting the 
MEME results is that the model used to compute positive selection probabilities assumes that codons 
evolve by base substitutions.  In hypervariable regions, this assumption is violated, and frequent inser-
tions and deletions dominate the mutational framework.  This is readily evident in the full alignment, 
but to illustrate it further, Tables S1 and S2 (in the Supplement) list each distinct variant form of the 
V1 and V5 hypervariable regions sampled from subject CH505.  This shows clearly the effects of in-
sertions and deletions on the evolution of these regions.  MEME identified some of these positions, as 
it should, but the p- and q-values are not readily interpreted in the context of the evolutionary model.  
LASSIE also identifies V1 and V5 hypervariable regions as candidates for positive selection, simply 
by counting changes from the transmitted-founder state over time. 
Outside of the V1 and V5 hypervariable regions, MEME identified an additional site with a q-value 
below 0.2, which LASSIE did not identify.  This site, HXB2 position 411 (codon 493) was in the 
known CTL epitope, HXB2 positions 409-418 (codons 491-500) [16], which may confer CTL re-
sistance.  The TF frequency for this site never falls below 40% in a time-point.  While this site is likely 
driven by immune selection, incomplete resistance or viral fitness costs associated with escape muta-
tions at this site presumably make other local escape mutations more competitive.  Regardless, this site 
may be of interest, and with LASSIE one could include it with the list of sites for consideration during 
the sequence-selection phase of analysis, if desired.  An additional 14 sites identified by LASSIE were 
also found by MEME with a more inclusive p-value (false-positive rate) cutoff of 0.1, meaning they 
did not withstand the correction for multiple tests in MEME, but were identified as interesting by both 
methods. 
A class of sites likely to be of biological interest is those captured by LASSIE and missed by 
MEME.  These sites in CH505 are HXB2 positions 4, 234, 300, 302, 325, 330, and 412 (Table 1 and 
Figure 3) and are illustrated in Figure S1 to show the TF loss pattern clearly. These sites generally 
have either a single mutation (or very few) among internal branches of a phylogenetic reconstruction, 
and cannot be statistically validated using an approach like MEME.  However, once such a mutation 
emerges, the TF form is essentially lost, and replaced by the mutation, a selective sweep.  LASSIE 
identified 7 such sites, which MEME and another phylogeny-based method, FEL [59], did not.  Muta-
tions in such sites are good candidates for changes that confer a profound selective advantage, due to 
immune selection, viral fitness, or both.  Once they are introduced, lineages that survive to later time-
points all carry the mutation. 
In addition to site 411 in the CTL epitope, MEME identified 27 more sites with p-values below 0.1 
and q-values above 0.2 (Figure S2), which LASSIE did not find.  Most of these mutations were transi-
ent, rare, or not obviously related to the epitopes we know were targeted in CH505.  For example, 
many of these sites occurred in gp41 (Figure S2). 
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3.1.5. Threshold Considerations 
To consider systematically what sites might be missed by the 80% peak TF-loss criterion we used 
here (Figure 4), we explored the locations of mutated sites that did not attain 80% TF loss at any time-
point in the study period.  The 365 sites that varied were dispersed over the entire protein, as expected.  
In particular, sites that had only one mutation among all available sequences are scattered throughout 
the structure.  By requiring multiple mutations among all 385 available sequences, regional patterns 
appeared in the spatial distribution of mutations (Figure S3).  Positions with as few as three or four 
mutations began to show a clear focus towards the immunologically targeted regions.  This suggests 
that the relatively high threshold of 80% TF loss at any one time-point excludes from consideration 
some mutations that occur in immune-targeted regions, which may have phenotypic consequences for 
immunological sensitivity.  Several more localized clusters of sites were apparent, which contained 
variable positions but did not attain the within-time-point 80% TF loss cutoff criterion (Figure S3).  
Such structural clustering suggests presence of other selected regions.  However, these sites were not 
under the same high degree of selective pressure as sites in which the TF form was depleted.  These 
sites may be targets for transient or less potent antibodies, or antibodies that are just beginning to im-
pose selective pressure at the end of the study period.  They might otherwise result from CTL escape, 
tolerance of neutral variation, or other mechanisms of molecular change not directly related to immune 
selection.  LASSIE allows investigators to target the most highly selected sites for further study, and 
adjust the threshold as practical for reagent design. 
3.1.6. Concatamers of Selected Sites 
A concise representation of selected sites strings the sites together to form concatamers of 35 amino 
acids.  The order of sites in concatamers can, but need not, follow the primary Env sequence; here we 
ordered them by when non-TF mutations first emerged.  Modified sequence logos [74,75], in which 
symbol height indicates frequency in a sample, clearly show this progression over time (Figure 6). 
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Figure 6. Variant frequency across 35 sites selected from CH505 Env gp160.  (a) 
Population variant frequencies, computed from all 385 aligned sequences. (b) Temporal 
development of variant frequencies.  To emphasize TF loss progression, frequency of the 
TF form below the first row is blank.  Each row corresponds to one time-point sampled for 
the three-year study period, days 0-1121 (d0000 through d1121).  (c) Variant frequencies in 
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swarm set of 54 selected Envs.  Symbol height is proportional to amino acid frequency per 
site.  Colors correspond to Figure 3.  The gaps inserted to maintain the alignment appear as 
grey boxes to represent indels.  Site order follows ranks listed in Table 1. 
The top row (Figure 6a) summarizes variant frequencies per site from all 385 Envs sequenced over 
the first three years of infection in this individual.  Below that (Figure 6b), rows were stratified to 
summarize frequency in each sample, first for the TF virus (day 0), then for 14 plasma samples (day 
28–day 1121, i.e. week 4–week 160, post-infection).  Electrostatic charges of amino-acid side chains, 
depicted by symbol colors (cf. Figure 3), changed polarity in 25% of the gp120 sites (279, 144h, 463e, 
460, 347, 356, 275, 147) but not in gp41 sites.  Gain or loss of potentially glycosylated asparagines (O) 
appeared in 13 of the 32 (41%) gp120 sites, but none of the gp41 sites.  The swarm of representative 
sequences selected by the next stage of analysis (Section 3.2) was also depicted in this manner (Figure 
6c). 
Comparing timing of TF loss in the CH505 virus population with neutralization titers assayed longi-
tudinally from contemporaneous plasmas (Figure S4) suggests that neutralization breadth follows Env 
diversification in selected sites.  Autologous neutralization is evident at week 14, and heterologous 
neutralization breadth continues to increase thereafter.  TF loss at selected sites starts to emerge at 
week 4 and net TF loss at all selected sites combined continues to increase until the end of the time-
period studied. 
3.2. Swarm Selection 
We designed and implemented a simple, efficient algorithm to select sequences that represent vari-
ants at sites selected by TF loss.  The approach is greedy, meaning it adds variants iteratively, rather 
than refine the entire set for potentially better solutions.  Although such a greedy approach is unlikely 
to give the best possible overall solution, in situations where addition of variants leads monotonically 
to better solutions with diminishing returns, a greedy algorithm efficiently provides reasonably good 
approximations to the optimum solution [53], and can be refined to include other criteria as needed.  
The algorithm starts with the alignment used to select sites, and assumes that sample time-points can 
be identified from sequence names.  A merit of the approach is that, by considering the time of sam-
pling, it starts with sequences most like the form that established the infection.  It then progressively 
builds diversity in a manner that follows the natural course of infection.  In this way, common muta-
tions and mutations that eventually reach fixation are sampled repeatedly in varied genetic contexts.  
3.2.1. Representative Variants Among Selected Sites 
The algorithm identified 54 Envs that covered variant diversity at the 35 sites selected by TF loss.  
Table 2 summarizes these as concatamers.  The LASSIE algorithm selection criteria had at least two 
clear consequences.  First, the gradual accumulation of mutations found in early infection was deliber-
ately mimicked using this strategy.  Second, the appearance of each new mutation of interest is, by 
design, relatively isolated from other accumulating mutations emerging in the within-host virus popu-
lation.  Therefore, to the extent possible with the given sampling, each mutation in each selected site 
was expressed in a context as close as possible to the form of the Env in which it appeared when it first 
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began to emerge in the viral population at a level high enough to be sampled.  Thus, if a particular mu-
tation conferred a phenotypic change in either antigenicity or neutralization susceptibility of an isolate, 
then that change would be included for study in its natural context. Selected mutations that appear ear-
ly, but are retained at later time-points, are resampled together with later variants (Table 2). 
Table 2. Selected Envs.  Concatamers (35 sites with at least 80% TF loss) in antigenic swarm of 54 
Envs, selected to represent polymorphisms among 385 Env gp160s from CH505.  Dots match TF state. 
Name Accession Concatamer 
w000.TF KC247556 NHVTNO---VADYNTK--N-KOKIHEGOOETDMGR 
w004.31 KC247583 .....................-............. 
w004.54 KC247604 K.................................. 
w007.8 KM284749 KR................................. 
w007.21 KM284732 ..................................Q 
w007.25 KM284734 ............................N...... 
w007.34 KM284744 ...I............................... 
w008.20 KM284762 ..A................................ 
w009.19 KM284781 ..G................................ 
w010.7 KM284714 .N................................. 
w020.15 KC247489 ....OS....T........................ 
w020.11 KC47485 ..........TN....................... 
w020.24 KC247495 .RA......AT........................ 
w020.25 KC247496 .R....ATO.......................... 
w022.6 KC247523 ..AIOSATO...H...................... 
w022.5 KC247522 .RA.OSATO....S..................... 
w022.9 KC247525 ..GIOS.................-........... 
w022.22 KM284717 ...O............................... 
w030.20 KC247541 ..AIOSATOA......TNTO............... 
w030.17 KC247532 D.GOOSATO.......TD................. 
w030.21 KC247535 .RA.OSATO...........E.............. 
w030.36 KC247549 ....OSATO.....O.TD................. 
w030.26 KC247539 .RG.OS....-....NTD................. 
w030.13 KC247529 ..DPOS............................. 
w030.32 KC247546 .RG.OSATO.......TD-................ 
w053.15 KC247614 D.G.OSATOA..HSONFT.E.-.L........... 
w053.29 KC247625 .RAIOSATOA..HSONFT.E.-....E........ 
w053.22 KC247620 DRGIOSIEIAG.HSONFT.E.TE............ 
w053.8 KC247632 DRGIOSATOA..HSONFT.E.T..Q.......... 
w053.31 KC247628 DRGIOSAT....HSON....N-............. 
w053.9 KC247633 DRGIOSIEIAG.HSONFT.E.TE....N..I.... 
w078.6 KC247664 DRGIOSOS.AS.HSONTN.OE-............. 
w078.36 KC247655 DRGIOSTAAAS.HSON..S.O-.-....SD..... 
w078.9 KC247667 DRG.OSTAA.S.HSONFT.E....QK..S...... 
w078.26 KC247645 DRGIOSTAAAS.HSON..S.O.E.NK..S...... 
w078.29 KC247647 DRGIOSTAAAS.HSONTN..-..-L..NS.A.... 
w078.30 KC247649 ..A.OSATOA..HSON....N-......D...... 
w078.33 KC247652 ..A.OSATOA..HSONT.O.N-.....N..I.T.. 
w078.17 KC247639 DRG.OSATOA..HSONFT.EE..LDK.D..IG... 
w078.15 KC247637 DRGIOSATOA..HSON..D..TEL.KES....... 
w078.27 KC247646 DRGIOSATOA..HSONTDD..TEL.KES....R.. 
w100.T3 KC247401 DRGIOSATO..NHSONTDD.ETEL.KEN..I.RS. 
w100.B10 KC247386 DSG.OSATOA..HSONTDD....LDKEN..I.... 
w100.B2 KC247387 .RAIOSIK.AG.HSON....N...D.V........ 
w100.B4 KC247389 DRGIOSATO...HSON..S.O...DKE.K....D. 
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Name Accession Concatamer 
w100.A11 KC247376 D.S.OSATOA..HSONTNTOE-..D.E.KD..... 
w100.A13 KC247378 ..A.OSATOAV.HSONTNTOE-.......D..... 
w136.B10 KC247404 D.GIOSATOADNHSONTD.E-TELDKES.DIY.S. 
w136.B5 KC247429 ..A.OSATOAV.HSONTESK-.E.O..Y.DI.... 
w136.B2 KC247411 D.G.OSTVAA-.HGONIDOT--E.O.......RD. 
w136.B23 KC247414 D.A.OSIK..G.HSONTEST-..VD....N...D. 
w160.C1 KC247465 ..A.OSVTOAV.HSONTGST-...D..Y.D..TV. 
w160.T3 KC247482 D.SIOSATOA.NHSONTD.E-TELDKVND.IGRD- 
w160.T4 KC247483 D.A.OSTVA.S.HSONPD..-...G...DN..... 
 
Swarm variant frequencies (Figure 6c) resembled variant frequencies sampled in the virus popula-
tion (Figure 6a), with additions of under-represented mutations at selected sites, which were less read-
ily apparent in the larger population.  Mutations seen only once among all of the sequences obtained 
were not required for inclusion, but all mutations in selected sites seen in two or more of all the se-
quences were represented by the 54 selected Envs.  Mutations that occurred only once were not con-
sidered, as they are more likely to represent random mutations or possible sequencing error than recur-
ring mutations.  Increasing this setting to include each mutation only if it occurs more often will de-
crease the number of Envs selected. 
3.2.2. LASSIE Compared with Randomly Selected Sequences 
We performed a resampling experiment to evaluate the swarm-selection algorithm against a null 
distribution, which might be sampled naively by less informed methods.  The null distribution was 
sampled randomly from full-length Envs that had been normalized to eliminate multiple copies of the 
same Env sequence.  Removing duplicates and excluding Envs with premature stop or incomplete co-
dons gave 260 distinct Envs, from which we repeatedly resampled the same number of sequences as in 
the swarm set (54 Envs) without replacement.  Figure 7 compares the null distribution from resampled 
results with the algorithmically chosen swarm.  By design, in our set of 54 selected Envs, no concata-
mers were duplicated, i.e. each Env carried a distinct combination of amino acids in the 35 positions of 
interest, and all recurrent mutations in selected sites were represented.  Because the sites represented 
progressive adaptation of the virus in CH505, we expect each concatamer to have distinct antigenic 
and/or phenotypic properties, including sensitivity to the coevolving antibody response, which could 
be identified by assaying each variant against longitudinally obtained plasmas or mAbs isolated to rep-
resent a developing clonal lineage (Section 3.2.4).  In contrast, among the randomly chosen sets of 54 
Envs, redundant concatamers of selected sites were common.  Resampling 1,000 replicates gave a me-
dian of 40 distinct concatamers with 95% CI from 34 to 45 (Figure 7a). 
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Figure 7. The selected swarm set is distinct from randomly selected sets.  (a) Number 
of distinct concatamers, mutations included, and clustering coefficients from dendrograms 
of concatamer distances differ for the selected swarm of 54 Envs (red) and the null distri-
bution from 1,000 sets of 54 Envs, randomly selected without replacement from the non-
redundant set of 260 viable full-length Envs, with the TF form always included.  Values 
have jitter added for less overplotting.  (b) Clustering coefficient quantifies sequence dif-
ferences among as the average normalized distance at which each sequence is merged into 
a cluster (horizontal grey bars in bottom row), compared for the selected and swarm set 
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two extreme randomly sampled sets (min and max, circled points in the right-hand plot in 
panel a, above). 
We also compared how many of the non-TF mutations tabulated in the first pass of the algorithm 
through all 385 sequences were covered.  The antigen swarm set selected using LASSIE was designed 
to cover all 92 distinct mutations that arose in the 35 selected sites.  As expected, random sampling of 
Envs gave consistently lower coverage of the mutations of interest (median 77; 95% CI: 69 to 84) than 
the 92 mutations that were included by the swarm-selection algorithm (Figure 7a).  This indicates that 
random sets of the same size do not capture all of the mutations we consider to have the most potential 
relevance to immune selection in general, and antibody sensitivity in particular. 
Further, we computed hierarchical dendrograms from Hamming distance matrices for swarm and 
random sets, and summarized the outcomes as clustering coefficients.  The results shown here were 
obtained using the single-linkage method, which is related to the minimum spanning tree [76].  The 
strength of the clustering can be measured as a dimensionless number between zero and one called the 
agglomerative coefficient [77].  It is the mean normalized distance at which each sequence clusters 
with others, and characterizes how well the data are clustered together.  To provide an intuition for 
how this coefficient works, Figure 7 also shows the dendrogram from the swarm set and compares it 
with the resampled sets that gave lowest (“min”) and highest (“max”) coefficients.  The LASSIE se-
lected Envs had a lower clustering coefficient (65%) than sets of randomly selected sequences, which 
had a median of 79% and 95% CI: 72-80% (Figure 7).  The lower clustering coefficient indicates less 
hierarchical grouping structure, i.e. a more uniform distribution over the available sequence space or 
lower overall relatedness among subsets of concatamers from the selected Envs, than exhibited by the 
random sequence sets [77]. 
These metrics compared sequence sets from the swarm selection algorithm with null distributions 
that were obtained by random selection.  Because the three metrics are only loosely correlated, they 
measure different aspects of selected sets of sequences.  To our knowledge, this is the first attempt to 
establish criteria to quantify how well any subset of sequences from a larger related set represents di-
versity (number of distinct concatamers), polymorphisms (number of recurrent mutations included), 
and progressive divergence (clustering coefficient) of the larger set.  We suggest these objective crite-
ria may be useful to choose representative sets of sequences, regardless of how they may be chosen; 
the smallest set of sequences that maximizes these three criteria, given an ordered list of selected sites, 
would then be considered the optimal sequence subset when choosing representative reagents. 
3.2.3. Phylogenetic Context 
A consideration of the phylogenetic context of Envs included in the swarm set shows the persis-
tence of selected sites against a scattered background of ephemeral mutations (Figure 8). 
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Figure 8.  Env variants in phylogenetic context.  A pixel plot is paired with the maxi-
mum-likelihood phylogeny, such that each row depicts one of 385 Envs sequenced by lim-
iting-dilution PCR.  The top row corresponds to the TF virus.  In the pixel plot (left), sites 
that match the TF are blank and mutations are shaded indicate gain of negatively (red) or 
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positively charged amino acids (blue), addition of an N-linked glycosylation motif (cyan), 
indels (black), or other mutations (grey).  The colored vertical stripes that emerge with time 
correspond roughly to TF loss.  Env landmarks appear as vertical bands throughout the 
pixel plot (light grey), and dashed lines delineate the signal peptide and gp41.  Tree 
branches and symbols are color-coded to indicate sample time-point, and the 54 selected 
Envs are marked by a black circle and horizontal bar. 
Selected Envs were widely distributed over the phylogeny.  The earliest selected Envs (weeks 4-10) 
tended to carry single mutations, which are often carried forward and represented again by Envs at 
later time-points.  Some later Envs represented large clades sampled only in one or two time-points, 
such as the sequence w160.T3 (KC247482), which appears almost at the bottom of the tree (Figure 8). 
3.2.4. Antigenic Diversity 
We opted to work with data from subject CH505 for initial LASSIE development and testing not 
only because a large set of longitudinal sequences was already published and available, but also be-
cause roughly one-fourth of the Env sequences from CH505 had been hand-selected and previously 
expressed as pseudovirus and proteins, then subjected to immunological evaluations [15,16].  These 
available data provided an opportunity to explore the antigenic diversity and neutralization sensitivity 
represented by a large subset of the antigenic swarm that LASSIE selected.  Of note, the sequences we 
had originally used to analyze the CH505 immune response had been chosen manually from the phy-
logenetic tree, a practice typical in this field.  Combined uncertainty about how well the manual selec-
tion covered all immunologically relevant mutations in CH505, how effectively it recapitulated the 
gradually emerging resistance to evolving antibody clonal lineages, and a desire to minimize the ex-
pense of building very large subject-specific Env reagent sets in future studies, all motivated develop-
ment of LASSIE.  LASSIE provided a principled solution for the first two of these biological prob-
lems, coverage and mimicking in vivo antigen evolution, while defining a minimal set of Envs to 
achieve these ends, and minimize experimental costs. 
ELISA binding assays with mAbs from the CH505-derived CH103 CD4 binding site bnAb B cell 
lineage were available for 94 gp120s; a subset of 27 LASSIE-selected Envs were included in this set 
(Figure 9).  Binding assay results confirmed that selected viruses exhibited diverse antibody sensitivi-
ties, which increased with maturation of the bnAb lineage and generally followed the progression of 
mutations away from the TF virus (Figure 9). 
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Figure 9. Selected Envs represent diverse binding phenotypes.  Among the swarm of 54 
Envs selected, 27 were synthesized as gp120s for ELISA binding assays (red text).  Anoth-
er four of the antigens tested contained selected sites that matched with those in selected 
Envs (purple text).  Binding data are shown as colors to indicate log-transformed area un-
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der the curve (AUC) from dilution series, which summarized experimental results better 
than EC50s.  Both assays tested Env constructs against monoclonal antibodies of the 
CH103 lineage, from mAb isolates (e.g. CH103) to the unmutated ancestor (UCA) via in-
termediate ancestors IA1-IA8 [15].  Blank entries indicate no binding was detected.  Se-
lected Env sites correspond to concatamers in Table 2.  An “X” appears for gp41 sites, 
which were not in the gp120 antigens tested.  Data are listed in Table S3. 
In a similar manner for neutralization sensitivity, 26 LASSIE-selected Envs were among 121 Env-
pseudotyped viruses tested for neutralization sensitivity by CH103 lineage mAbs [16] (Figure 10).  
Selected Envs represented the range of sensitivities among viruses tested, reflecting the diversity of 
variants that developed in response to sustained selection for neutralization escape. 
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Figure 10. Selected Envs represent diverse neutralization phenotypes.  Among the 
swarm of 54 Envs, 26 were cloned into pseudovirus backbones for TZM-bl neutralization 
assays (red text).  Another four of the Env-pseudotyped virus constructs tested contained 
selected sites that matched with those in selected Envs (purple text).  Neutralization IC50s 
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are represented as colors to indicate sensitivity of each virus to neutralization by each mAb 
in the CH103 lineage.  Selected Env sites correspond to concatamers listed in Table 2.  
The values appear in Table S4. 
In Figure S5 (in the Supplement), neutralization titers from all previously hand-selected viruses 
clearly show the development of neutralization breadth in phylogenetic context.  Envs at the top of the 
tree are broadly susceptible to many antibodies in the CH103 lineage.  Envs that evolved later appear 
lower in the tree.  Neutralization breadth was acquired later in bnAb ontogeny, which is clear as a gra-
dient of increasing potency from the unmutated ancestor (left) to the mature CH103 bnAb (right).  By 
selecting Envs that represent genetic diversity sampled during bnAb development, the method selects 
Envs that represent relevant antigenicity over time. 
3.3. Swarm Size Adjustments 
We have used the LASSIE approach to analyze samples from two individuals with larger data sets 
that are currently in preparation.  To reduce the number of Envs for inclusion in reagent design below 
100 from over 1000 initially sampled sequences (as compared to 385 sequences sampled from CH505) 
required that we increase the TF loss cutoff above 90%.  Selecting an antigenic swarm of fewer than 
100 sequences also required increasing the frequency of rare amino acids for representation in the 
swarm.  Both of these adjustments focused outcomes on sites that ranked highest in terms of selective 
pressure (TF loss threshold) and the mutations within these sites that are most successful under host 
immune pressure (minimum variant count). 
Another way to reduce the number of sites and sequences that result from LASSIE is to exclude 
sites that were insertions relative to the TF sequence, which occurs most frequently in the hypervaria-
ble loops.  Due to the evolutionary processes that yield length polymorphisms, rather than point muta-
tions, and the resulting difficulty of consistently aligning homologous sites in these regions, we natu-
rally found disproportionately high diversity of V1, V2, V4, and V5 sites among selected Envs.  Re-
sources to produce reagents that capture each recurring point mutation in the hypervariable loops 
might be better allocated elsewhere.  Excluding such sites from the list of selected sites used to choose 
sequences reduced the number of sequences, while still representing diversity of envelope regions with 
well-defined structure.  However, because these length polymorphisms in variable regions are known 
to be involved with immune escape (e.g. [73]), representation of the most common forms found in the 
hypervariable regions should be still included in swarm sets.  When exploring the option of excluding 
TF insertions from the selection criteria, we found that different forms of hypervariable loops were 
indeed still included in the antigenic swarm, but their representation was of course limited to evolu-
tionary contexts in which they occurred together with sites that have high TF loss.  When considering 
this alternative, one should ensure that the common forms of hypervariable-region variants, such as we 
have listed in Tables S1 and S2 as having the greatest numbers of times observed, are included among 
the antigenic swarm identified by LASSIE.  If not, they might be added as specific additional sites or 
sequences to the reagent set (see Methods). 
3.4. Chronic Infection 
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These methods were developed initially to select sequences from longitudinal studies beginning ear-
ly in infection, where the TF virus is reliably inferred, and the progression of escape mutations is readi-
ly apparent.  This is obviously not true for chronic infection.  Still, it is often necessary to select a sub-
set of sequences that represent diversity in serial samples taken during chronic infection.  To evaluate 
the algorithm’s ability to select an antigenic swarm from a chronic infection, we applied it to sequenc-
es from a study participant enrolled during chronic infection, designated CH0457 [56].  We analyzed 
205 plasma SGA Envs from ten sample time-points (median was 20 sequences per time-point; the dis-
tribution ranged from 12 to 35).  In the chronic enrollment sample, the first available, five of twenty 
Envs exactly matched the within-time-point consensus.  We used one of these as the reference to com-
pute variant frequencies.  No variation was detected in 582 of 888 aligned sites, and an 85% cutoff 
identified 35 sites that were candidates for strong positive selection (Figure S6).  Nine of the 35 sites 
are located in gp41. 
With singleton variants excluded, the algorithm selected a swarm of 44 Envs (Figure S7).  The pro-
gressive accumulation of mutations among concatamers of selected sites is less clear in this chronically 
infected subject than in acute infection (cf. Figure 6b).  Furthermore, sites that appear to be under se-
lection in the interval sampled are not clearly associated with two epitope regions, as was the case of 
CH505, where there was a strong imprint of CD4bs and V3 antibodies selection, and indeed antibodies 
with these specificities were isolated from the subject.  In the case of CH0457, most of the selected 
sites were not identified as relevant to known antibodies, although two sites were in the MPER region 
of gp41 (HXB2 positions 667 and 671) and two sites were predicted signatures of the 2F5 MPER anti-
body (positions 640 and 351).  In addition, one site was in contact with some CD4bs antibodies: a 
changing glycosylation pattern at 461, which contacts CD4 and the CD4bs bnAbs VRC01 and NIH45-
46.  Two of the selected sites (651 and 640) have been noted to be CD4bs antibody signatures [67].  A 
potent CD4bs bnAb CH27 was isolated from subject CH0457, but the virus isolated from CH0457 
plasma had escaped from this antibody by the time of enrollment [56].  However, archived provirus 
from CH0457 cell-associated DNA remained sensitive to neutralization by bnAb CH27 [56].  CH13, a 
weaker CD4bs nAb capable of neutralizing only heterologous tier 1 viruses, was isolated, and may 
have been exerting selective pressure in the last weeks sampled [56]. 
The phylogeny indicated a persistent, divergent secondary clade, represented by 24 of 205 plasma 
Envs (Figure S8).  This clade was not introduced by misalignment nor by simple recombination, and 
was also represented by cellular provirus sequences [56].  Though the divergent clade was undetected 
among sequences from the enrollment sample, it was represented by 14 of the 44 Envs selected (Fig-
ure S7).  Thus, the algorithm can be applied to both acute and chronic Env sequential sequence analy-
sis and swarm design. 
4. Discussion 
Vertical stripes of mutations in an aligned set of serially sampled sequences, as shown in Figures 2 
and 8, indicate sites where the transmitted-founder amino acids are lost over time, a useful criterion to 
identify candidate selected sites.  We have presented a systematic approach to identify these sites, track 
their dynamics graphically, and then identify protein sequences that capture mutations in the selected 
sites as they first emerge in the quasispecies.  The task of selecting representative variants from a larg-
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er set for follow-up studies from longitudinal samples can be complex when choosing from hundreds 
to thousands of sequences.  LASSIE divides the task into two main parts, automatically identifies and 
tracks selected sites within a subject, and identifies sequences that represent antigenic diversification in 
that subject. 
First, we use transmitted-founder loss in a longitudinal study as a simple way to identify sites under 
positive selection pressure.  Despite the existence of a variety of methods to test for positive selection 
by comparing rates of synonymous versus non-synonymous substitution, their utility to identify sites 
under positive selection in the limited diversity context of within-subject viral evolution is limited by 
statistical power [44,78].  For example, the strong selective pressure may be exhibited by a single 
change in a phylogenic reconstruction, as illustrated in Figure S1.  This could happen with a popula-
tion bottleneck, or an advantageous mutation or mutations that are strongly favored being carried for-
ward through recombination.  Also, allele frequencies can be biased by removing identical sequences 
in order to obtain dichotomously branching trees.  Identical seuquences are unlikely to occur among 
samples from different hosts, but commonplace when sampling from acute through early infection 
within a host [5,15,16,46,47]. 
In contrast, loss of the TF form at any time-point is a simple and inclusive measure.  In CH505, 
sites selected by this criterion were focused in regions highly relevant to the known adaptive immune 
responses previously identified in the subject [15,16].  This suggested that in future studies, structural 
localization of selected sites could be used to raise hypotheses about specificities of bnAbs in plasma.  
Furthermore, the timing of TF loss identifies these important mutational events and could help deter-
mine when antibodies are exerting the most selective pressure, indicative of which samples in a longi-
tudinal series are likely to yield antibodies with particular specificities, and when the earliest members 
of a clonal lineage that target a particular epitope first appear.  Such information could help efforts to 
isolate monoclonal antibodies in subjects with potent nAbs, by focusing on antibody specificities that 
recognize the epitopes under selection, and by identifying which samples might best be used to isolate 
new bnAbs from subjects sampled over several years of follow-up. 
Admittedly, the TF loss criterion alone cannot distinguish between sites that represent a random 
sweep, where a mutation is established in a lineage by chance, and selected sites.  This is why we refer 
to the set of sites LASSIE identifies as candidates for sites under positive selection.  For example, 
LASSIE could identify a neutral mutation genetically linked to another mutation under positive 
selection.  We aim to be inclusive and evaluate immunological phenotypes of such patterns in our 
swarm sets, to ascertain which mutations are indeed escape mutations.  In this way, LASSIE is 
designed to minimize type II errors, even with a small cost of increased type I error.  Also, even if a 
mutation were neutral when it first arose, and subsequently maintained in the population, it may 
represent a pre-adaptive state that allows novel escape mutations to accrue that depend on the presence 
of the initally neutral mutation.  LASSIE “swarms” bring each new mutation into the swarm in the Env 
genetic context in which it was first sampled, in the simplest form possible, relative to the evolving 
quasispecies.  Thus, subsequent immunological experiments can identify immune-sensitive phenotypic 
profiles between Envs with minimal amino-acid changes between them.  This helps to isolate the 
candidate sites under pressure from immune selection, to the extent possible in the context of 
appropriate Envs. 
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Second, we provide a rational, objective method to guide the selection of Env sets for experimental 
study from large sequence sets sampled over time.  LASSIE can select sets of sequences that represent 
gradual antigenic diversification induced during bnAb development, ensuring that all variants in sites 
identified by TF loss are represented in an Env reagent set, while minimizing redundancy, and select-
ing only as many variants as are necessary to represent diversity in sites selected by TF loss.  For a set 
of aligned sequences sampled from an acute, single-founder infection, the algorithm starts with se-
quences most like the form that established the infection, and gradually increases diversity in a manner 
that parallels natural infection.  Though a smaller set of sequences could be defined that minimally 
cover all variants at selected sites, the gradual accumulation of mutations would not be captured by 
such minimal set, and more subtle transitions may be critical for selection of bnAb breadth, i.e. evolv-
ing antibodies may adapt more readily to serial introductions of single mutations in an epitope, rather 
than to those same changes introduced simultaneously. 
We used LASSIE to identify selected sites and representative sequence subsets in longitudinal sam-
ples from one acutely infected subject and one subject sampled only during chronic infection.  We 
analyzed SGA sequences, which provide intact env gp160 genes with no recombination artifacts and 
minimal error [5,14,21,45-47].  While such data provide ideal conditions, the approach could also be 
used in other longitudinal study designs and sequencing strategies (e.g. [41]). 
In related research, sequence selection has been represented as a set-coverage problem [79], to iden-
tify networks of covarying sites in a population-level alignment, which represents a particular clade 
[80], rather than a serially sampled, within-subject alignment as in this study.  A limitation of our ap-
proach, which we intend to address in the future, is that sites are treated independently, while covaria-
tion between sites may influence variant suitability and TF loss.  Considering covariation may poten-
tially facilitate identification of smaller representative swarm sets, and may better accommodate ram-
pant recombination between divergent lineages within a host. 
By progressively adopting mutations in the context of variant sequences where they first arise in our 
sequence sets, our swarm sets – by definition – allow the study of mutations in the context of the natu-
ral combinations of mutations as they occurred in vivo.  This strategy could complement, or in some 
instances provide sufficient information to replace, traditionally used site-specific mutagenesis, which 
necessarily studies mutations in isolation.  As mentioned above, a mutation observed in a later time-
point and introduced into the TF, for example, may not be viable or may not have the same phenotypic 
consequences as it does in the background of the Env in which it arose, so the ability to study related 
natural variants isolated serially may ultimately be more informative. 
A working hypothesis to explain the observation that bnAbs tend to arise late infection, after anti-
genic diversification has arisen in the subject, is that serial immune escape in vivo drives antibody line-
ages to adapt to the emerging viral variants, and eventually enable recognition of diverse forms of the 
targeted epitope from the circulating population [16,18].  Exposure of a neutralizing antibody lineage 
during affinity maturation to increasing antigen diversity could result in selection of antibodies with 
increased breadth [15,18,31,37,38].  Mimicking in vivo diversification has therefore been proposed as 
a possible vaccination strategy for bnAb induction [15,18,81-83].  Related work has suggested that 
Env variants sampled during development of heterologous neutralization breadth could be adminis-
tered as immunogens [84-86]. 
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With recent technological advances, it is becoming feasible to test vaccine designs that not only in-
clude 5-10 antigens, but potentially between 50-100 antigens, administered as DNA either in series or 
in combination [87,88].  Because LASSIE uses an efficient algorithm to identify candidate sets of anti-
gens with progressively increasing diversity at important sites in polymorphic viral proteins, it could 
be used to help with the design of such antigen-swarm vaccines.  This method could be applied to oth-
er large, longitudinally sampled sets of sequences, such as from hepatitis C virus [89-93].  Use of this 
method to analyze antibody sequences, which complement the evolving viral sequences, could identify 
selected sites and select a representative subset of sequences from antibody clonal lineages. 
5. Conclusions 
In summary, we have developed computational methods to identify and track selected sites in longi-
tudinal sequence data, and to use these selected sites to aid in down-selecting sequence sets for reagent 
design, or for testing the “antigenic swarm” vaccine concept.  When applied to longitudinal HIV sam-
ples, a retrospective evaluation of viral sequences from the intensively studied subject CH505 showed 
that the LASSIE provided meaningful results.  High TF loss highlights mutations in selected sites that 
were indeed under immune selective pressure.  An efficient algorithm builds a non-redundant collec-
tion of sequences tailored to characterize the phenotypic consequences of the mutations in those sites.  
LASSIE may be useful in many contexts, for reagent selection, to assist with bnAb isolation, potential-
ly for vaccine design, as well studies of other viral infections, and studies of antibody evolution. 
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Supplementary Materials 
 
 
Figure S1. Sites with high TF loss not detected by MEME.  The 7 sites selected with over 
80% peak TF loss that were not selected by MEME (q-values above 0.2 and p-values 
above 0.1) show abrupt transitions from the TF to a mutated amino acid, described as dy-
namic category i in the Section 3.1.1 of the main text.  For clarity, mutations that never at-
tain 15% frequency in any sample are not shown. 
 
 
Figure S2. Sites without high TF loss detected with positive selection by MEME.  The 28 
sites selected by MEME with q-values below 0.2 and p-values above 0.1, which were not 
selected by the 80% peak TF loss criterion, included dynamic categories i, iii, and iv de-
scribed in Section 3.1.1 of the main text, and included at least 4 sites without dynamics. 
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Figure S3. Locations of selected and non-selected Env sites in CH505.  (a) Sites select-
ed by high TF loss are depicted by beads, whose colors indicate when each site exceeded 
10% TF loss, as listed in Table 1.  For structural context, the immunologically relevant mu-
tations and regions described in Fig 4 are also shown.  V1 sites missing from the structure 
are illustrated schematically (top left).  (b) Sites that mutated only once among 385 CH505 
Env sequences (0.25% TF loss over all time-points), and present in the structure, are identi-
fied by lilac beads.  These sites were not selected, due to low TF loss.  (c) Sites with two or 
more mutations among 385 CH505 Env sequences (at least 0.5% TF loss over all time-
points), but less than 80% peak TF loss, are marked by lilac beads. 
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Figure S4. Comparative timing of TF loss and neutralization breadth.  Sample times 
(weeks post-infection) increase from top to bottom, and align sequence logos (left) from 
Figure 5b with neutralization titers from contemporaneous plasmas tested against autolo-
gous virus (CH0505.TF), a panel of five Tier 1 envelope pseudotyped viruses (SF162 
through BG1168), and sixteen Tier 2 viruses (Q842.d12 through AC10.0.29).  ID50 titers 
below the sensitivity limit of 20 µg/ml are indicated by grey, and darker red colors indicate 
greater neutralization potency.  The clade of each virus (A, B, or C) appears before its 
name. 
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Figure S5. CH505 Env variants and antibody development.  Neutralization IC50 titers 
and ELISA log-AUC binding affinities of hand-picked envelopes from assays against the 
CH103 bnAb lineage are juxtaposed with the Env polymorphism and phylogeny shown in 
Figure 8.  Column order for bnAb titers follows that shown in Figures 9 and 10 (from left 
to right: UCA, IA8, IA7, IA6, IA5, IA4, IA3, CH105, IA2, CH104, IA1, CH106, CH103). 
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Figure S6. Number of sites varied with cutoff in chronically infected donor CH0457.  
Increasing the cutoff decreased number of sites. 
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Figure S7. Variant frequencies among selected sites in chronic infection.  Frequencies 
from CH0457, computed among (A) all sequences, pooled; (B) sequences stratified by 
time; and (C) 44 selected Envs.  Colors indicate positive (blue) and negative (red) charges 
and “O” indicates a potentially gylcosylated asparagine (cyan).  Indels appear as grey box-
es. 
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Figure S8. Diversity in chronic infection.  CH0457 Env mutations (left), neutralization 
ID50 titers against autologous contemporaneous plasmas (center), and maximum-
likelihood Env phylogeny (right).  The 44 selected Envs are emphasized among all Envs 
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sampled.  The divergent clade appears above the “Time Sampled” legend.  This representa-
tion follows Figure 8, with neutralization titers, one column per time-point.  Neutralization 
responses were profiled for 84 Env-pseudotyped viruses chosen before the swarm-selection 
algorithm existed, and tested against autologous sera from each time-point sampled. 
Table S1. V1 hypervariable region.  This table shows variants in HXB2 positions 136 through 145, 
codons 199-215 in the CH505 alignment, a region not present in the transmitted-founder virus.  This 
region accepted many distinct insertions, up to 17 amino acids long, often followed by deletions within 
the insertion, or subsequent mutations, throughout the period of the infection sampled.  We found 29 
distinct forms in this region.  An example of each unique sequence selected from the first time-point in 
which each pattern was observed, with a representative sequence named, which includes the time of 
isolation, in weeks post-infection.  The V1 loop noted in the Los Alamos database spans positions 
HXB2 132-153.  In subject CH505 indels in this broader region are almost certainly also impacting 
evolutionary patterns.  Dashes maintain alignment consistency. 
Example 
sequence V1 Insertion 
Number  
of times 
observed 
w000.TF ----------------- 211 
w020.19 AS------------NAT 19 
w020.28 ASN----------TNAT 3 
w022.10 --------------NAT 74 
w022.17 -------------TNAT 12 
w030.18 A-------------NAT 11 
w030.33 TSNSS------------ 1 
w030.19 AR---------NCTNAT 1 
w030.32 ASNSSI-----NCTNAT 1 
w053.2 ASNATAS-------NAT 5 
w053.22 A---TASNS----SIIE 11 
w053.13 ASNATASNS----SIIE 3 
w078.42 ASNATASNATAS---NS 2 
w078.34 ASNATASNATAS-NTTA 1 
w078.16 T-NATASNATAS-NATA 2 
w078.36 ASNATASNATAS-NATA 7 
w078.5 ATASNTNATAS-NINAT 12 
w078.33 ATAS----------NAT 1 
w100.A3 ATASNSSI-------IK 3 
w100.T2 ATAS--------NINAT 3 
w100.A13 ATASNANATAS-NTNAT 2 
w136.B7 D----ANATASNTNATV 1 
w136.B2 ATASNTNATVSNIKATV 1 
w136.B3 ATASNANATASNTNATV 1 
w136.B24 ATASNA--TASNTNATA 1 
w136.B23 DTASNSSI-------IK 3 
w160.C1 ANATASNI------NVT 1 
w160.C12 ATASNANATVSNTNATV 3 
w160.D6 --------------NTT 1 
Longitudinal Antigenic Swarm Selection from Intrahost Evolution Hraber et al. 
 
Page 44 of 55 
Table S2. V5 hypervariable region. This table summarizes variants in HXB2 positions 463 through 
466, spanning codons 546-552 in the CH505 alignment, a region that was not present in the transmit-
ted-founder virus.  This region accepted many distinct insertions, up to 7 amino acids long, often fol-
lowed by deletions within the insertion, or subsequent mutations, throughout the period of the infection 
sampled.  We found 21 distinct forms of indels in this region.  We selected an example of each unique 
sequence from the time-point in which each pattern was first observed, and a representative sequence 
named, which includes the week of isolation.  The V5 loop region noted in the Los Alamos database 
spans HXB2 positions 460-467.  In subject CH505, indels in this broader region are almost certainly 
also impacting the evolutionary patterns.  Dashes maintain the alignment. 
Example 
sequence V5 Insertion 
Number 
of times 
observed 
w000.TF ------- 241 
w030.11 -----DT 40 
w030.20 DGGKNNT 1 
w053.15 ----ETF 40 
w078.42 -GGKNNT 5 
w078.16 --GKNNT 1 
w078.29 -----NT 1 
w078.33 ------T 1 
w078.5 -RGKNNT 1 
w100.B7 DGGNNNT 11 
w136.B1 ----EDT 38 
w136.B23 ----TET 5 
w136.B5 ----KET 4 
w136.B26 ----NDT 1 
w136.B28 ---DTDT 1 
w136.B2 -----DI 1 
w136.B7 -----DM 1 
w160.C3 -----DP 2 
w160.C10 ETSETVS 1 
w160.C1 ----TGT 1 
w160.C6 ----EGT 1 
Table S3. ELISA binding assay log-AUC of CH103 lineage Abs against autologous Env gp120s. 
gp120 UCA IA8 IA7 IA6 IA4 IA3 CH105 IA2 CH104 IA1 CH106 CH103 
w000.TF 3.5 5.5 9.2 9.1 10.1 11 11.2 10.8 10.4 10.4 11.3 12.6 
w004.26 3.2 5.5 9.1 9 9.5 10.4 10.4 10.6 11.1 10.3 11 12.4 
w004.54 <0.1 0.5 2.3 2.9 2.8 5.1 8.3 6.8 8.1 6.2 8.1 9.2 
w014.10 0.3 2.2 5.1 6.3 7.1 9 10.8 9.9 10.7 9.4 10.4 11.9 
w014.2 0.8 3.2 7.2 6.9 8.5 9.7 9.6 9.7 9.5 9.1 9.6 10.9 
w014.21 0.4 2.8 6.2 7.8 8 9.4 11.4 10.2 11.4 9.7 11.1 13.1 
w014.3 1 4.4 7.7 7.6 9.2 10.3 10.8 10.6 10.6 9.6 10.6 11.9 
w014.32 1.6 4.2 7.9 7.8 8.5 9.9 10.7 10.2 10.9 9.5 10.5 11.9 
w014.8 <0.1 0.9 0.6 2.4 2.6 1.8 6 3.6 3.9 3.4 7.9 11.2 
w020.11 <0.1 0.9 0.1 0.8 0.8 0.8 3.6 2.6 2.2 1.8 5.4 9.6 
w020.14 0.3 3.4 7.2 7.9 8.6 9.5 10.4 11 10.4 10.3 11.2 12.6 
w020.15 1.6 4.2 8.2 7.8 9.1 10.2 10.8 10.5 10.5 9.9 10.5 11.8 
w020.19 0.8 3.5 7.2 6.5 8.1 9.4 9.5 9.3 9.7 9 9.7 11.3 
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gp120 UCA IA8 IA7 IA6 IA4 IA3 CH105 IA2 CH104 IA1 CH106 CH103 
w020.22 1.2 4 8.3 8.4 8.8 10.2 10.5 10.6 10.7 10.1 10.7 11.5 
w020.23 0.9 3.6 7.2 7.9 8.6 9.7 11.2 10.7 11.6 9.8 11.3 12.8 
w020.25 0.8 2.4 6.4 6 7.3 8.6 8.2 9 8.3 8.6 9.4 10.3 
w020.26 <0.1 0.7 2.7 4 5.1 7.1 9 9 8.7 8.9 9.6 11.3 
w020.3 0.8 2.6 5.9 6 7 7.7 10.1 9.3 9.8 8.9 10.3 12.4 
w020.30 0.8 4.2 7.3 7.9 8.5 9 10.3 10.5 10.1 9.8 10.8 11.7 
w020.4 0.9 3.6 8.2 8.7 9.4 10.6 11.1 11.6 11.6 11.3 11.5 12.5 
w020.7 0.6 2.7 7.6 8.1 8.7 10.4 10.6 11.3 11.1 10.8 11.3 12.5 
w020.8 0.4 2.6 5.9 6.7 7.4 8.8 10.6 10.5 10.5 9.9 11 12.4 
w020.9 0.4 2.8 4.9 6.8 7.4 8.1 9.3 9.7 8.9 9 10 11.9 
w030.10 0.2 1.3 3.2 5.1 5.8 7.3 9.3 11 10.3 10.1 11.1 12.5 
w030.11 <0.1 <0.1 0.7 0.5 0.5 2.4 9 9.1 9.5 8.4 9.4 10.9 
w030.12 <0.1 0.4 1 1.2 1.9 4.1 10.7 11.6 11.6 10.6 11.8 13.3 
w030.13 0.3 2 4.7 6.5 7.4 9 10.5 11.4 11.3 10.5 11.9 12.9 
w030.15 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 9.3 8.4 9.7 8 9.3 10.1 
w030.17 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 6.7 7 7 5.8 8.2 9.9 
w030.18 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 11.1 9.4 10.9 9.9 10.5 13 
w030.19 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 9.5 8.2 8.9 8.2 7.4 12.9 
w030.20 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 7.1 6.3 7.5 5.7 7.3 9.5 
w030.21 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 10.6 11.5 11.3 11.8 10.9 12.2 
w030.23 <0.1 <0.1 <0.1 <0.1 <0.1 0.7 9.2 8.9 9.6 8.4 10 11.1 
w030.25 <0.1 <0.1 0.4 0.5 0.4 1.4 10 9.9 10.3 9.1 10.2 12.5 
w030.27 <0.1 <0.1 <0.1 <0.1 <0.1 0.4 7.9 7.9 8.2 7.3 8.2 9.1 
w030.28 <0.1 1.6 3.5 6.3 6.5 7.7 9.1 11.1 10.7 10.1 11.7 12.8 
w030.36 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 7.5 7.3 7.8 6.7 8.5 9.1 
w030.5 <0.1 <0.1 <0.1 <0.1 <0.1 0.3 9 8.1 9.4 7.8 9.4 11.4 
w030.6 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 6.5 5.4 6.1 4.5 6.6 8 
w030.9 <0.1 <0.1 <0.1 <0.1 <0.1 0.2 8.7 8.6 8.9 7.8 9.6 10.2 
w053.13 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 9.4 10.5 10 9.9 10.2 11.2 
w053.15 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 9.4 9.5 10.4 9.2 10.1 11.2 
w053.19 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 13.8 12.6 13.8 13.6 13.2 13.5 
w053.22 <0.1 <0.1 <0.1 <0.1 0.2 1.1 9 9.3 9.9 8.8 9.8 11.6 
w053.25 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 10 10.2 10.6 10 10.9 11.6 
w053.29 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 8.5 9.2 9.8 8.8 9.7 10.2 
w053.31 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 13.5 13.3 13.7 13.4 13.4 13.6 
w053.6 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 11.7 11.9 12 11.4 10.9 12.7 
w078.1 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 7.5 7.7 8.3 7.5 7.3 11 
w078.10 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 7.6 6.6 8.1 6.6 7.8 11.1 
w078.15 <0.1 <0.1 0.7 1 1.3 3 10.1 11.5 10.8 10.9 11 10.7 
w078.17 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 9.5 9.9 10 9 8.7 11.3 
w078.25 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 3.3 3.2 3.5 2.4 4.6 8.7 
w078.33 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 8.9 9 9 8.2 9.5 11.1 
w078.38 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 4 4.7 4.2 4.4 5.3 7.7 
w078.4 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 9.5 10.2 10.1 9.8 9.2 11.7 
w078.5 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 6.6 6.6 7.7 5.6 7.9 10.2 
w078.6 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 3.8 4.6 4.5 3 6.7 9.9 
w078.7 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 9.4 9.2 9.5 8.9 8.7 11.4 
w078.9 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 6.6 7.2 6.9 6.3 8.3 8.9 
w100.A10 <0.1 <0.1 <0.1 <0.1 <0.1 0.1 9.1 10.5 10.1 9.9 10.4 11.7 
w100.A12 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 9.6 9.4 10.4 8.6 9.7 4.7 
w100.A13 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 11.4 12.5 12.9 12.6 12 12.9 
w100.A3 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 7.2 9.3 10 8.5 8.6 11.4 
w100.A4 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 8.1 9 9.1 8.6 9 10.7 
w100.A6 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 10.1 11.4 11.6 11 11.1 12.1 
w100.B2 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 7.5 7.5 6.1 7.3 7.8 3.2 
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gp120 UCA IA8 IA7 IA6 IA4 IA3 CH105 IA2 CH104 IA1 CH106 CH103 
w100.B4 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 11.9 13.4 13.1 13.7 12.6 9.7 
w100.B6 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 11 12.1 11 12.2 11.8 7.1 
w100.B7 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 11.6 12.4 11.6 11.9 11.5 7.8 
w100.C7 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 9 9.1 9.2 8.9 9.3 4.8 
w136.B10 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 8.5 9.7 8.9 9.2 9 11.5 
w136.B12 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 9.7 12.4 10.7 12.2 11.9 12.7 
w136.B2 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 12.4 13.1 13.2 13.2 12.7 10.8 
w136.B20 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 10.7 12.7 11.7 12.4 12.1 12.4 
w136.B23 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 13.7 14.3 14.2 14.4 13.3 11.8 
w136.B27 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 10.4 11.9 11.5 11.2 11.2 12.6 
w136.B29 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 10.2 12.5 11.4 12.2 12 12.7 
w136.B3 <0.1 <0.1 <0.1 <0.1 <0.1 0.1 12 13.1 13.1 13.1 12.6 9.9 
w136.B36 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 12.8 13.6 13.8 13.8 13.1 13.7 
w136.B4 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 10.7 12.2 12.2 11.8 11.8 13.4 
w136.B5 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 10.5 9.9 10.6 9.5 10.9 4.3 
w136.B8 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 9.9 13.2 11.7 12.9 11.7 11.9 
w160.A1 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 6.7 7.6 7.3 6.4 7.6 10.7 
w160.C11 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 7.7 8.5 7.4 7.7 8.2 11.9 
w160.C12 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 11.1 12.9 11.3 12.9 12.2 7.8 
w160.C14 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 6.6 7 6.8 5.8 6.9 12.1 
w160.C2 <0.1 <0.1 <0.1 <0.1 <0.1 1.3 8.6 10.1 9.2 9.6 9.3 12.2 
w160.C4 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 6.6 6.2 7.2 5.3 6.8 12.2 
w160.D1 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 6 7.3 5.7 6.4 7.1 11.5 
w160.D5 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 4.6 5 4.5 3.8 5.6 10.9 
w160.T2 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 4.9 5.6 5.4 4.7 6.2 11.2 
w160.T4 <0.1 <0.1 <0.1 <0.1 <0.1 <0.1 12.2 13.4 12.8 13.6 12.3 9 
Table S4. TZM-bl neutralization IC50 titers of CH103 lineage Abs with autologous env gp160s. 
gp160 UCA IA8 IA7 IA6 IA5 IA4 IA3 CH105 IA2 CH104 IA1 CH106 CH103 
w000.TF >50 44.67 10.17 10.17 6.82 9.72 6.62 5.1 2.73 3.08 1.42 2.29 4.14 
w004.03 15.12 2.05 0.71 0.99 0.13 0.67 0.85 0.38 0.29 0.29 0.16 0.16 0.13 
w004.08 >50 16.75 4.2 4.11 3.38 3.24 6.09 2.92 1.29 1.62 0.95 1.39 1.89 
w004.10 >50 41.36 8.66 5.32 5.66 3.8 3.68 2.44 1.17 1.31 0.74 0.71 1.1 
w004.11 >50 >50 14.35 10.32 8.17 8.76 7.71 3.62 2.79 2.32 1.71 1.2 2.37 
w004.13 >50 25.24 3.08 3.5 9.78 4.08 7.88 3.4 3.46 2.09 1.45 1.08 3.15 
w004.14 >50 47.61 11.92 9.71 13.78 11.02 10.62 5.22 3.53 2.34 2.14 1.32 4 
w004.15 >50 >50 16.45 9.82 6.43 8.2 6.23 4.03 1.92 1.49 1.34 1.41 1.37 
w004.16 >50 21.26 8.43 4.33 7.32 6.95 6.4 4.33 2.78 2.66 1.39 1.23 2.83 
w004.26 19.5 1.5 0.77 0.88 0.07 0.67 0.41 0.24 0.15 0.27 0.25 0.09 0.24 
w004.27 >50 12.39 2.32 2.57 4.69 2.7 5.7 2.4 1.89 1.44 1.17 0.53 1.94 
w004.29 >50 31.68 5.57 4.72 2.48 4.7 3.4 2.24 1.3 1.36 1.1 0.79 1.9 
w004.37 >50 25.63 8.66 7.97 4.76 5.61 4.15 2.19 1.68 1.65 1 0.43 1.87 
w004.51 >50 34.15 6.83 5.77 8.62 6.54 5.45 2.11 1.54 1.59 1.36 0.56 2.04 
w004.56 >50 34.78 8.46 8.51 6.42 6.35 5.83 3.36 2 1.59 1.39 0.8 2.4 
w014.10 >50 >50 28.28 29.42 25.98 28.93 4.98 2.82 1.72 1.9 1.27 0.98 1.6 
w014.16 >50 >50 42.21 27.23 32.29 18.85 11.75 8.42 4.3 4.48 4.08 4.45 6.27 
w014.19 >50 >50 15.49 10.14 20.09 9.2 6.06 4.39 1.82 2.47 1.36 2.47 4.66 
w014.2 >50 >50 26.66 14.92 25.33 13.63 10.3 6.84 2.28 3.24 2.87 2.86 4.01 
w014.20 >50 >50 23.56 12.68 20.3 15.94 6.27 3.02 1.96 1.88 1.07 1.43 2.92 
w014.21 >50 24.97 11.01 5.22 4.07 3.36 0.94 0.6 0.39 0.37 0.24 0.41 0.53 
w014.29 >50 >50 37.65 39.45 >50 22.36 14.88 12.54 5.66 6.14 4.02 6.33 6.91 
w014.3 >50 >50 23.5 13.51 8.13 10.07 5.83 3.64 1.18 1.69 1.84 1.45 2.57 
w014.30 >50 >50 >50 46.59 39.45 34.46 15.52 8.11 4.94 4.2 3.01 3.41 6.17 
w014.31 >50 >50 36.38 25.99 31.67 28.03 13.04 7.22 4.05 3.69 4.28 3.19 5.84 
w014.32 >50 >50 41.85 25.02 21.56 22.67 16 8.26 5.66 3.96 3.66 4.41 5.51 
w014.34 >50 >50 >50 43.94 48.04 49.79 22.64 11.24 7.05 5.72 5.09 4.66 7.32 
w014.39 >50 43.27 40.99 24.91 34.07 32.87 15.15 8.48 5.77 4.73 3.09 4.52 5.44 
w014.4 >50 >50 24.72 20.23 28.95 15.59 10.41 6.04 2.77 2.35 2.25 2.55 3.37 
w014.6 >50 >50 26.84 25.13 32.85 20.88 12.23 6.99 3.37 3.14 3.07 3.02 4.14 
w014.8 >50 28.47 23.12 17.3 34.15 12.93 8.81 4.59 1.06 1.41 1.54 1.6 1.06 
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gp160 UCA IA8 IA7 IA6 IA5 IA4 IA3 CH105 IA2 CH104 IA1 CH106 CH103 
w020.11 >50 32.68 21.45 13.04 4.41 12.53 5.97 1.82 1.14 0.85 1.17 0.61 0.43 
w020.13 >50 >50 >50 >50 19.84 31.77 20.17 14.16 6.7 5.6 3.62 6.15 5.82 
w020.14 >50 42.47 10.13 5.45 6.33 4.88 1.99 1.04 1.22 0.67 0.72 0.46 0.08 
w020.15 >50 >50 42.09 21 19.46 29.54 16.25 11.42 6.41 5.9 3.12 6.16 6.91 
w020.19 >50 >50 43.58 >50 43.43 >50 21.65 13.42 7.58 6.12 5.05 7.69 8.34 
w020.2 >50 >50 20.17 18.4 7.09 19.49 11.8 6.2 4.08 3.29 2.12 2.78 3.5 
w020.21 >50 >50 >50 29.58 >50 21.02 6.36 3.64 1.88 1.81 1.23 1.56 2.54 
w020.22 >50 >50 20.77 12.38 14.1 8.22 3.48 2.21 1.25 0.88 0.53 1.01 1.45 
w020.23 >50 26.79 8.07 4.74 10.6 3.45 2.65 1.48 1.12 0.87 0.54 0.68 0.87 
w020.24 >50 28.92 9.44 5.57 12.97 4.73 2.51 3.15 1.12 1.52 0.57 1.54 1.11 
w020.25 >50 >50 >50 >50 37.72 >50 23.37 14 11.15 9.01 6.41 7.96 7.95 
w020.26 >50 48.25 10.45 7.31 8.65 6.79 2.06 1.23 0.9 1.29 0.51 0.77 0.88 
w020.27 >50 >50 20.82 14.21 25.37 9.51 5.7 3.89 2.24 1.85 1.2 1.22 1.81 
w020.3 >50 >50 >50 24.06 4.17 22.41 4.93 2.35 1.63 1.46 0.77 1.04 1.41 
w020.4 >50 >50 25.99 9.46 3.98 11.83 2.77 1.36 0.88 0.6 0.55 0.67 0.67 
w020.7 >50 23.68 6.85 2.85 2.92 3.83 1.39 0.86 0.62 0.95 0.41 0.6 0.52 
w020.8 >50 >50 14.67 8.41 3.78 7.53 3.34 3.54 1.37 1.63 1.14 1.7 2.02 
w020.9 >50 14.87 5.46 2.07 4.3 3.06 3.62 1.92 1.16 1.33 1.06 1.13 1.37 
w030.10 >50 >50 >50 35 6.93 23.97 8.07 3.88 1.11 1.08 1.61 1.14 1.56 
w030.12 >50 >50 36.65 25.87 6.44 18.39 1.92 1.88 0.52 0.95 0.65 0.62 1.11 
w030.13 >50 >50 >50 8.43 2.77 9.64 5.19 3.86 1 0.43 1.06 1.08 1.43 
w030.15 >50 >50 >50 >50 >50 >50 11.44 7.43 3.5 5.79 4.6 2.8 3.98 
w030.17 >50 >50 >50 >50 >50 >50 3.86 14.24 7.28 6.78 6.86 3.9 4.28 
w030.18 >50 >50 >50 >50 >50 >50 2.92 2.1 1.12 1.16 1.08 0.88 1.36 
w030.19 >50 >50 >50 >50 >50 >50 1.45 0.81 0.47 0.51 0.39 0.54 0.58 
w030.20 >50 >50 >50 >50 >50 >50 >50 44.19 20.42 28.33 31.48 17.56 13.2 
w030.21 >50 >50 >50 >50 >50 >50 2.35 1.49 0.43 0.53 0.62 0.56 1.05 
w030.23 >50 >50 >50 >50 >50 >50 33.12 23.24 18.56 12.81 17.21 9.39 9.51 
w030.25 >50 >50 >50 >50 >50 >50 20.19 12.84 11.02 8.69 12.9 7.7 11.99 
w030.26 >50 >50 >50 >50 >50 >50 >50 32.38 17.23 18.9 12.5 12.48 12.11 
w030.27 >50 >50 >50 >50 >50 >50 >50 >50 43.69 38.02 18.28 31.87 30.02 
w030.28 >50 44 23.07 7.18 3.78 6.92 4.35 2.13 0.77 0.59 0.49 0.77 0.77 
w030.31 >50 >50 >50 >50 >50 >50 43.08 27.73 11.73 9.79 6.71 10 8.79 
w030.32 >50 >50 >50 33.9 >50 40.93 2.56 2.89 1.09 1.52 0.54 1.25 1.03 
w030.34 >50 >50 >50 >50 >50 >50 >50 >50 44.85 47.07 49.72 39.83 26.37 
w030.36 >50 >50 >50 >50 >50 >50 >50 21.15 10.96 11.07 8.12 8.13 9.24 
w030.37 >50 >50 >50 >50 >50 >50 >50 >50 29.75 >50 25.19 40.42 22.3 
w030.5 >50 >50 >50 >50 >50 >50 45.16 34.12 6.76 7.45 9.67 10.04 8.05 
w030.6 >50 >50 >50 >50 >50 >50 15.27 9.23 1.3 1.3 4.99 4.51 4.15 
w030.8 >50 >50 >50 >50 >50 >50 >50 14.11 10.35 7.07 12.83 9.91 12.56 
w030.9 >50 >50 >50 >50 >50 >50 >50 >50 44.49 42.98 >50 19.82 49.94 
w053.10 >50 >50 >50 >50 >50 >50 >50 31.68 10.59 20.07 13.21 12.73 18.87 
w053.11 >50 >50 >50 >50 >50 >50 >50 >50 26.22 32.63 32.31 37.41 30.37 
w053.13 >50 >50 >50 >50 >50 >50 12.38 6.64 4.78 4.47 3.6 4.66 5.3 
w053.14 >50 >50 >50 >50 >50 >50 20.93 15.52 6 6.46 5.76 8.28 8.01 
w053.15 >50 >50 >50 >50 >50 >50 31.54 29.48 12.11 12.65 8.19 17.72 13.82 
w053.16 >50 >50 >50 >50 >50 >50 >50 21.73 10.68 3.44 17.37 18.39 12.31 
w053.17 >50 >50 >50 >50 >50 >50 43.24 20.89 10.62 7.25 10.32 13.8 10.61 
w053.19 >50 >50 >50 >50 >50 >50 4.58 2.84 2.59 2.66 1.91 2.55 3.16 
w053.22 >50 >50 >50 >50 >50 >50 41.2 29.51 15.81 12.31 11.58 19.36 12.19 
w053.25 >50 >50 >50 >50 >50 >50 43.14 28.05 13.07 10.1 7.56 10.47 9.26 
w053.27 >50 >50 >50 >50 >50 >50 >50 27.02 17.47 13.61 14.56 14.99 10.47 
w053.28 >50 >50 >50 >50 >50 >50 46.24 21.84 14.19 14.45 7.67 15.86 12.65 
w053.29 >50 >50 >50 >50 >50 >50 >50 42.24 21.79 17.38 14.58 22.52 21.95 
w053.3 >50 >50 >50 >50 >50 >50 49.31 27.54 10.51 8.82 4.42 9.46 8.37 
w053.31 >50 >50 >50 >50 >50 >50 2.38 2.06 1.06 1.09 0.43 1.68 1.24 
w053.32 >50 >50 >50 >50 >50 >50 22.8 13.89 7.53 6.29 6.09 10.78 6.76 
w053.6 >50 >50 >50 >50 >50 >50 >50 >50 19.43 19 16.67 12.57 11.88 
w053.8 >50 >50 >50 >50 >50 >50 >50 34.75 21.53 17.15 16.78 20.92 16.01 
w053.9 >50 >50 >50 >50 >50 >50 >50 >50 31.44 32.21 22.7 34.57 28.81 
w078.1 >50 >50 >50 >50 >50 >50 7.06 4.07 1.3 1.68 3.31 4.63 2.69 
w078.10 >50 >50 >50 >50 >50 >50 15.43 8.67 4.42 6.1 3.04 5.49 7.08 
w078.14 >50 >50 >50 >50 >50 >50 28.34 17.7 10.25 9.25 6.58 17.81 11.33 
w078.15 >50 >50 >50 >50 21.97 49.04 2.97 2.55 0.76 0.96 0.25 2.08 1.51 
w078.16 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 12.73 
w078.17 >50 >50 >50 >50 >50 >50 >50 30.44 16.62 14.81 9.56 26.32 15.23 
w078.25 >50 >50 >50 >50 >50 >50 30.45 10.5 21.4 22.67 29.85 15.19 17.72 
w078.3 >50 >50 >50 >50 >50 >50 7.14 5.34 2.28 3.11 1.41 5.17 3.74 
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gp160 UCA IA8 IA7 IA6 IA5 IA4 IA3 CH105 IA2 CH104 IA1 CH106 CH103 
w078.33 >50 >50 >50 >50 >50 >50 >50 28.41 12.23 11.06 15.79 12.2 4.13 
w078.38 >50 >50 >50 >50 >50 >50 33.25 15.49 13.81 12.51 13.26 12.85 12.32 
w078.4 >50 >50 >50 >50 >50 >50 >50 24.76 19.03 10.56 23.86 29.17 22.48 
w078.5 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 10.9 
w078.6 >50 >50 >50 >50 >50 >50 >50 >50 22.34 23.56 20.68 17.31 3.8 
w078.7 >50 >50 >50 >50 >50 >50 43.42 18.53 2.58 4.4 6.67 15.23 6.79 
w078.8 >50 >50 >50 >50 >50 >50 17.56 9.7 6.07 4.85 5.27 9.33 6.41 
w078.9 >50 >50 >50 >50 >50 >50 47.83 15.44 13.28 17.02 16.17 14 17.32 
w100.A10 >50 >50 >50 >50 >50 >50 >50 48.74 25.12 21.8 27.54 37.29 36.75 
w100.A11 >50 >50 >50 >50 >50 >50 >50 12.24 4.13 3.13 2.11 3.99 10.74 
w100.A12 >50 >50 >50 >50 >50 >50 33.48 20.53 13.17 10.77 5.98 17.72 18.02 
w100.A13 >50 >50 >50 >50 >50 >50 >50 17.24 3.96 3.49 10.36 6.63 26.34 
w100.A2 >50 >50 >50 >50 >50 >50 >50 25.34 4.85 7.63 3.42 9.21 21.36 
w100.A3 >50 >50 >50 >50 >50 >50 13.27 7.42 2.87 3.81 1.02 6.1 5.76 
w100.A4 >50 >50 >50 >50 >50 >50 >50 25.45 12.83 10.51 12.93 14.06 13.65 
w100.A5 >50 >50 >50 >50 >50 >50 >50 20.69 3.7 3.34 1.85 5.64 15.63 
w100.A6 >50 >50 >50 >50 >50 >50 16.02 12.64 5.79 5.27 6.34 12.01 11.51 
w100.B3 >50 >50 >50 >50 >50 >50 >50 12.56 3.18 3.42 2.06 4.64 10.72 
w100.B4 >50 >50 >50 >50 >50 >50 1.64 0.75 1.13 0.64 0.91 0.74 3.46 
w100.B6 >50 >50 >50 >50 >50 >50 >50 13.02 2.77 3 3.15 3.41 10.97 
w100.B7 >50 >50 >50 >50 >50 >50 41.77 14.31 4.89 3.66 2.38 5.38 11.33 
w100.B8 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 >50 44.9 
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